eMedicine Specialties > Radiology > Vascular/Interventional

Deep Venous Thrombosis, Lower Extremity

Eric K Hoffer, MD, Director, Vascular and Interventional Radiology, Associate Professor of Radiology, Section of Angiography and Interventional Radiology, Dartmouth-Hitchcock Medical Center
John J Borsa, MD, Consulting Staff, Department of Radiology, St Joseph Medical Center

Updated: Apr 10, 2009

Introduction

Background

Deep venous thrombosis (DVT) is the presence of coagulated blood, a thrombus, in one of the deep venous conduits that return blood to the heart. The clinical conundrum is that symptoms (pain and swelling) are often nonspecific or absent. However, if left untreated, the thrombus may become fragmented or dislodged and migrate to obstruct the arterial supply to the lung, causing a potentially life-threatening pulmonary embolus (PE).

DVT and PE are the manifestations of a single disease entity, namely, venous thromboembolism (VTE). In terms of incidence, lower-extremity DVT is the most common venous thrombosis, with a prevalence of 1 case per 1000 population. In addition, it is the underlying source of 90% of acute PEs, which cause 25,000 deaths per year in the United States (National Center for Health Statistics [NCHS], 2006). Other than the immediate threat of PE, the risk of long-term major disability from postthrombotic syndrome (PTS) is high.^1,2,3,4,5

Pathophysiology

In 1856, Virchow described the classic triad of predisposing factors for DVT, namely, venous stasis, injury of the vascular wall, and a hypercoagulable state.⁶ Events or conditions that alter the equilibrium of one or more of these factors may produce DVT.

Thrombosis is the homeostatic mechanism whereby blood coagulates or clots, a process crucial to the establishment of hemostasis after a wound. Several pathways initiate thrombosis and usually consisting of cascading activation of enzymes that magnify the effect of an initial trigger event. A similar complex of events results in fibrinolysis, or the dissolution of thrombi. The balance of trigger factors and enzymes is complex. Microscopic thrombus formation and thrombolysis (dissolution) are continuous events, but with increased stasis, procoagulant factors, or endothelial injury, the coagulation-fibrinolysis balance may favor the pathologic formation of an obstructive thrombus. Clinically relevant DVT is the persistent formation of macroscopic thrombus in the deep proximal veins.

In the absence of rhythmic contraction of the leg muscles, as in walking or moving, blood flow in the veins slows and even stops in some areas, predisposing patients to thrombosis.⁷

Thrombus usually forms behind valve cusps or at venous branch points, the majority of which begin in the calf. Venodilation may disrupt the endothelial cell barrier and expose the subendothelium. Platelets adhere to the subendothelial surface by means of von Willebrand factor or fibrinogen in the vessel wall. Neutrophils and platelets are activated, releasing procoagulant and inflammatory mediators. Neutrophils also adhere to the basement membrane and migrate into the subendothelium. Complexes form of the surface of platelets and increase the rate of thrombin generation and fibrin formation. Stimulated leukocytes irreversibly bind to endothelial receptors and extravasate into the vein wall by means of mural chemotaxis. Because mature thrombus composed of platelets, leukocytes and fibrin develops, and an active thrombotic and inflammatory process occurs at the inner surface of the vein, and an active inflammatory response occurs in the wall of the vein.^8,9

In the postoperative patient, up to one half of all isolated calf vein thrombi resolve spontaneously within a few hours, whereas approximately 15% extend to involve the femoral vein. A many as one third of untreated symptomatic calf vein DVTs extend to the proximal veins.¹⁰ At 1-month follow-up of untreated proximal DVT, 20% regress and 25% propagate. Although calf vein thrombi are rare sources of clinically significant PE, the incidence of PE with untreated proximal thrombi is 29-50%.^11,10 Most PEs are first diagnosed at autopsy.^12,13

Over a few months, most acute DVTs evolve to complete or partial recanalization, and collaterals develop (see Images below and Multimedia Images 2-3).^{14,15,16,17,18,19} Although blood flow may be restored, residual evidence of thrombus or stenosis is observed in one half of patients after 1 year. Furthermore, the damage to the underlying valves and those compromised by peripheral dilation and insufficiency usually persists and may progress. Venous stasis, venous reflux, and chronic edema are common in patients who have had a large DVT.²⁰

Lower-extremity venogram shows outlining of an acute deep venous thrombosis in the popliteal vein with contrast enhancement.

Lower-extremity venogram shows a nonocclusive chronic thrombus. The superficial femoral vein (lateral vein) has the appearance of 2 parallel veins, when in fact, it is 1 lumen containing a chronic linear thrombus. Although the chronic clot is not obstructive after it recanalizes, it effectively causes the venous valves to adhere in an open position, predisposing the patient to reflux in the involved segment.

Another mechanism that contributes to venous incompetence is the natural healing process of the thrombotic vein. The thrombotic mass is broken down over weeks to months by inflammatory reaction and fibrinolysis, and the valves and venous wall are altered by organization and ingrowth of smooth muscle cells and production of neointima. This process leaves damaged, incompetent, underlying valves, predisposing them to venous reflux. The mural inflammatory reaction breaks down collagen and elastin, leaving a noncompliant venous wall.^{9,14,15,16,17,18,19}

Persistent obstructive thrombus, coupled with valvular damage, ensures continuation of this cycle. Over time, the venous damage may become irreversible. Hemodynamic venous insufficiency is the underlying pathology of PTS. If numerous valves are affected, flow does not occur centrally unless the leg is elevated. Inadequate expulsion of venous blood results in stasis and a persistently elevated venous pressure or venous hypertension. As fibrin extravasates and inflammation occurs, the superficial tissues become edematous and hyperpigmented. With progression, fibrosis compromises tissue oxygenation, and ulceration may result. After venous insufficiency occurs, no treatment is ideal; elevation and use of compression stockings may compensate, or surgical thrombectomy or venous bypass may be attempted.^21,22,23,24

With anticoagulation alone, as many as 75% of patients with symptomatic DVT present with PTS at 5-10 years.^24,25 However, the incidence of venous ulceration is far less, at 5%. Of the half million patients with venous ulcers in the United States, 17-45% report having a history of DVT.²⁶

Mortality/Morbidity

The sequelae and treatment complications tend to be more problematic in chronic disease than the acute disease.

• DVT: DVT classically produces pain and limb edema. The classic finding of pain on dorsiflexion of the calf (Homans sign) is specific but insensitive and present in one half of patients with DVT.²⁷ Symptoms often resolve with symptomatic treatment because collateral flow develops; symptoms may be most persistent with iliac involvement. In relatively rare instances, acute extensive (lower leg–to-iliac) occlusion of venous outflow may create a blanched appearance of the leg because of edema. The clinical triad of pain, edema, and blanched appearance is termed phlegmasia alba dolens. This is also known as milk-leg syndrome when it is associated with compression of the iliac vein by the gravid uterus. If the collateral outflow veins are thrombosed, the appearance is dusky discoloration or cyanosis, which is phlegmasia cerulea dolens. As many as one half of patients with this condition have capillary involvement, which poses a risk of irreversible venous gangrene with massive fluid sequestration. In severely affected patients, immediate therapy is necessary to prevent limb loss.
• PE: As many as 40% of patients have silent PE when symptomatic DVT is diagnosed.²⁸ Approximately 4% of individuals treated for DVT develop symptomatic PE. Almost 1% of postoperative hospitalized patients develop PE (National Healthcare Quality Report [NHQR], 2003). The 10-12% mortality rate for PE in hospitalized patients underscores the need for prevention of this complication. Treatment options include anticoagulation therapy and placement of an IVC filter. If evidence of right-heart failure is present or if adequate oxygenation cannot be maintained, the thrombus may be removed with pharmacomechanical thrombolytic intervention.
• Paradoxic emboli: Although rare, paradoxic emboli can occur in patients with cardiac defects (usually atrial septal defect), who are at risk for the passage of emboli to the arterial circulation and resultant stroke or embolization of a peripheral artery. Patients can present after cardiac failure occurs late in life, with resultant bedrest that increases the risk for DVT.
• Recurrent DVT: Without treatment, one half of patients have a recurrent, symptomatic VTE event within 3 months. After anticoagulation for an unprovoked VTE event is discontinued, the incidence is 5-15% per year. Presentations are similar, with pain and edema. However, the diagnosis may be difficult (ie, differentiating acute from chronic thrombus). (See Nuclear Medicine below.) Recurrence increases the risk of PTS.
• Hemorrhage: Anticoagulation therapy for 3-6 months results in major bleeding complications in 3-10% of patients a.²⁹ High-risk populations (>65 y with a history of stroke, GI bleed, renal insufficiency, or diabetes) have a 5-23% risk of having major hemorrhage at 90 days. Patients who require year-long or indefinite anticoagulation (because of chronic risk factors) have double the risk of hemorrhage.
• PTS: PTS is a chronic complication of DVT that manifests months to many years after the initial event. Symptoms range from mild erythema and localized induration to massive extremity swelling and ulceration, usually exacerbated by standing and relieved by elevation of the extremity. Evaluations of the incidence or of improvements with therapy have been problematic because reporting is not standardized. Furthermore, correlation between objectively measured hemodynamic changes and the severity of PTS is poor.³⁰ After symptomatic DVT is treated with anticoagulation, the incidence of PTS at 2 years is 25-50% despite long-term anticoagulation for iliofemoral DVT, and after 7-10 years, the incidence is 70-90%.^31,32 The only current treatment is use of a compression hose and elevation. In many patients, this is only partly effective in relieving swelling, pain, and venous ulcers. In the United States, the annual direct cost of post-DVT PTS-related venous ulcers is estimated to be $45 million per year, and 300,000 work days are lost.{Ref177}}

Anatomy

Deep venous thrombosis (DVT) is often divided into proximal and distal thromboses. The proximal veins are the popliteal, femoral (also known as superficial femoral), deep femoral, common femoral, and iliac veins and the inferior vena cava (IVC). Calf-vein DVT involves at least 1 of the paired deep calf veins: anterior tibial, posterior tibial, peroneal, or deep muscular veins. Calf-vein DVT is rarely a cause of symptomatic PE (Buller, 2004). Proximal DVT is reported to produce relatively severe symptoms and consequences related both to the congestion of collateral veins and to the risk of PE.³⁰

Presentation

Risk factors

Numerous factors, often in combination, contribute to DVT. These may be categorized as acquired (eg, medication, illness) or congenital (eg, anatomic variant, enzyme deficiency, mutation). A useful categorization may be an acute provoking condition versus a chronic condition, as this distinction affects the length of anticoagulant therapy.

The most common risk factors are obesity, previous VTE, malignancy, surgery, and immobility. Each is found in 20-30% of patients. Hospitalized and nursing home patients often have several risk factors and account for one half of all DVTs (with an incidence of 1 case per 100 population).^12,33

Venous stasis

The frequent causes of DVT are due to augmentation of venous stasis due to immobilization or central venous obstruction. Immobility can be as transient as that occurring during a transcontinental airplane flight or that during an operation under general anesthesia. It can also be extended, as during hospitalization for pelvic, hip, or spinal surgery, or due to stroke or paraplegia. Individuals in these circumstances warrant surveillance, prophylaxis, and treatment if they develop DVT.^34,35

Increased blood viscosity may decrease venous blood flow. This change may be due to an increase in the cellular component of the blood in polycythemia rubra vera or thrombocytosis or a decrease in the fluid component due to dehydration.

Increased central venous pressure, either mechanical or functional, may reduce the flow in the veins of the leg. Mass effect on the iliac veins or IVC from neoplasm, pregnancy, stenosis, or congenital anomaly increases outflow resistance.

Anatomic variants that result in diminution or absence of the IVC or iliac veins may contribute to venous stasis. In iliocaval thromboses, an underlying anatomic contributor is identified in 60-80% of patients. The best-known anomaly is compression of left common iliac vein at the anatomic crossing of the right common iliac artery. The vein normally passes under the right common iliac artery during its normal course (see Image 1).

In some individuals, this anatomy results in compression of the left iliac vein and can lead to band or web formation, subsequent stasis, and left leg DVT. The reasons are poorly understood. Compression of the iliac vein is also called May-Thurner syndrome or Cockett syndrome.

IVC variants are uncommon. Anomalous development is most commonly detected and diagnosed on cross-sectional imaging or venography. The embryologic evolution of the IVC is from an enlargement or atrophy of paired supracardinal and subcardinal veins. Anomalous embryologic development may result in absence of the normal cava. These variations may increase the risk of symptoms because small-caliber vessels may be most subject to obstruction. In patients younger than 50 years who have DVT, the incidence of a caval anomaly is as high as 5%.³⁶

A double or duplicated IVC results from lack of atrophy in part of the left supracardinal vein, resulting in a duplicate structure to the left of the aorta. The common form is a partial paired IVC that connects the left common iliac and left renal veins. When caval interruption, such as placement of a filter, is planned, these alternate pathways must be considered. As an alternative, the IVC may not develop. The most common alternate route for blood flow is through the azygous vein, which enlarges to compensate. If a venous stenosis is present at the communication of iliac veins and azygous vein, back pressure can result in insufficiency, stasis, or thrombosis.³⁷

In rare cases, neither the IVC nor the azygous vein develops, and the iliac veins drain through internal iliac collaterals to the hemorrhoidal veins and superior mesenteric vein to the portal system of the liver. Hepatic venous drainage to the atrium is patent. Because this pathway involves small hemorrhoidal vessels, thrombosis of these veins can cause severe acute swelling of the legs.

Thrombosis of the IVC is a rare occurrence and is an unusual result of leg DVT unless an IVC filter is present and stops a large embolus in the cava, resulting in obstruction and extension of thrombosis. Common causes of caval thrombosis include tumors involving the kidney or liver, tumors invading the IVC, compression of the IVC by extrinsic mass, and retroperitoneal fibrosis.^38,39

Hypercoagulability

Researchers have identified inherited hypercoagulable states as contributing risk factors in many cases of DVT, particularly recurrent DVT. Genetic thrombophilia is identified in 30% of patients with idiopathic venous thrombosis. Altered procoagulant enzyme proteins include factor V, factor VIII, factor IX, factor XI, and prothrombin. Altered or diminished anticoagulants include protein C and protein S.^40,41

Factor V Leiden is a mutation that results in a form of factor Va resists degradation by activated protein C, leading to a hypercoagulable state. Its importance lies in the 5% prevalence in the American population and its association with a 3- to 6-fold increased risk for VTE . Antiphospholipid syndrome is considered a disorder of the immune system, where antiphospholipid antibodies (cardiolipin or lupus anticoagulant antibodies) are associated with a syndrome of hypercoagulability. Although not a normal blood component, the antiphospholipid antibody may be asymptomatic. It is present in 2% of the population, and it may be detected in association with infections or the administration of certain drugs, including antibiotics, cocaine, hydralazine, procainamide, and quinine.⁴¹

Tests for these genetic defects are often not performed in patients with recurrent venous thrombosis because therapy remains symptomatic. In most patients with these genetic defects, lifetime anticoagulation therapy with warfarin (Coumadin) or low molecular weight heparin (LMWH) is recommended after recurrent DVT without an alternative identifiable etiology is documented. The risk of recurrent DVT is multiplied 1.4-2 times, with the most common genetic polymorphisms predisposing individuals to DVT. However, the low incidence of factor V Leiden and prothrombin G20210A may not warrant aggressive prophylaxis. Therefore, genetic testing might not be warranted until a second event occurs.⁴²

Other diseases and states can induce hypercoagulability in patients without other underlying risks for DVT. They can predispose patients to DVT, though their ability to cause DVT without intrinsic hypercoagulability is in question. The conditions include malignancy, dehydration, and use of medications (eg, estrogens). Acute hypercoagulable states also occur, as in disseminated intravascular coagulopathy (DIC) resulting from infection or heparin-induced thrombocytopenia.⁴³

Injury to the vessel wall

Injury may be obvious, such as those due to trauma, surgical intervention, or iatrogenic injury, but they may also be obscure, such as those due to remote DVT (perhaps asymptomatic) or minor (forgotten) trauma. Previous DVT is a major risk factor for further DVT. The increased incidence of DVT in the setting of acute urinary tract or respiratory infection may be due to an inflammation-induced alteration in endothelial function.

The presence of risk factors plays a prominent role in the assessing the pretest probability of DVT. Furthermore, transient risk factors permit successful short-term anticoagulation, whereas idiopathic DVT or chronic or persistent risk factors warrant long-term therapy.

Clinical evaluation

DVT and thromboembolism remain a common cause of morbidity and mortality in bedridden or hospitalized patients, as well as generally healthy individuals. The annual incidence of DVT in the United States is estimated to be 250,000, or 48 cases per 100,000 population. In the elderly, the incidence is increased 4-fold. The reported incidence of PE with or without DVT is 23-69 cases per 100,000 population, and 25,000 per year die from PE. The in-hospital case-fatality rate for VTE is 12%, rising to 21% in the elderly.

VTE remains an underdiagnosed disease, and most PEs are diagnosed at autopsy. Diagnosis depends on a high level of clinical suspicion and the presence of risk factors that prompt diagnostic study. Because the presentation is nonspecific and because the consequence of missing the diagnosis is serious, it must be excluded whenever it is a feasible differential diagnosis. Because the prevalence of the disease is 15-30% in the population at clinical risk, a widely applicable (inexpensive and simple) screening test is required.

Conclusive diagnosis historically required invasive and expensive venography, which is still considered the criterion standard. Since 1990, the diagnosis has been obtained noninvasively by means of (still expensive) sonographic exam (see Ultrasound). The recent validation of the simpler and cheaper D-dimer test as an initial screening test permits a rapid, widely applicable screening that may reduce the rate of missed diagnoses. Algorithms are based on pretest probabilities and D-dimer results. As many of 40% of patients with a low clinical suspicion and a negative D-dimer result require no further evaluation.^44,45

Treatment

Traditional therapy entails anticoagulation with intravenous (IV) unfractionated heparin (UFH) and conversion to oral warfarin to prevent further clot formation. Treatment guidelines from the American College of Chest Physicians (ACCP) recommend LMWH or UFH for 5 days in conjunction with a vitamin K antagonist (eg, warfarin) until an international normalized ratio (INR) of greater than 2 is stable. At that time, heparin can be discontinued.

Acute DVT may be treated in an outpatient setting with LMWH. Anticoagulant therapy is recommended for 3-12 months depending on site of thrombosis and on the ongoing presence of risk factors. If DVT recurs, if a chronic hypercoagulability is identified, or if a PE is life threatening, lifetime anticoagulation therapy may be recommended. This treatment protocol has a cumulative risk of bleeding complications of less than 12%.

Anticoagulant therapy remains the mainstay of medical therapy for DVT because it is noninvasive, it treats most patients (¡Ý90%) with no immediate demonstrable physical sequelae of DVT, it has a low risk of complications, and its outcome data demonstrate an improvement in morbidity and mortality. Meta-analyses of randomized trials of UFH and LMWH showed that they were similar, with risk of recurrent DVT of 4%, a risk of PE of 2%, and a risk of major bleeding of 3%.^46,47

Anticoagulation does have problems. Although it inhibits propagation, it does not remove the thrombus, and a variable risk of clinically significant bleeding is observed. In 2-4% of patients, DVT progresses to symptomatic PE despite anticoagulation. In the setting of a PE, 8% of patients have recurrences despite anticoagulation, 30-45% of which are fatal. Although anticoagulation markedly reducing the risk of PE and extension of the DVT, it does not reduce the incidence of PTS, which requires expedited removal of the existing thrombus without damaging the underlying venous valves.

Systemic IV thrombolysis once improved the rate of thrombosed vein recanalization; however, it is no longer recommended because of an elevated incidence of bleeding complications, slightly increased risk of death, and insignificant improvement in PTS. The lack of a significantly reduced incidence of PTS after systemic thrombolysis (40-60%) likely reflects the inadequacy of the relatively low threshold volume of thrombus removal that was considered successful.

Percutaneous transcatheter therapy of DVT is aimed at removing the thrombus and/or preventing PE. PE prevention is achieved by mean of caval interruption with an IVC filter. Pharmacologic thrombolysis entails the administration of enzymes to reduce the hypercoagulable component of the triad and to shift the balance to thrombus removal. Direct administration of a thrombolytic into the thrombus during percutaneous catheter-directed thrombolysis (CDT) is most effective approach. Significant lysis is achieved in 12% of patients with anticoagulation, in 30% receiving a systemic administration of a thrombolytic, and in 80% with CDT. Furthermore, the transvenous approach allows for treatment of an underlying venous stenosis by means angioplasty (balloon dilation) or stent placement. The cost of rapid, more complete lysis is reflected in the major risk of bleeding, which is increased to 8-11% with CDT.

As discussed, the immediate symptoms of DVT often resolve with anticoagulation alone, and the rationale for intervention is often reduction of the 75% long-term risk of PTS. Patients' negative assessments of the trade-off between an increased risk of major bleeding in exchange for a potentially decreased risk of PTS has reduced the use of systemic thrombolysis. The bleeding risk is similar to that of CDT, and the risk of PTS may further decrease risk. However, whether CDT is preferred to anticoagulation has not been examined. The addition of percutaneous mechanical thrombectomy to the interventional options may facilitate decision-making, because recanalization may be achieved faster than before and with a decreased dose of lytic; therefore, the bleeding risk may be decreased.

Differential diagnoses

Of patients evaluated for DVT of the lower extremity, only a quarter of them have the disease. DVT is characterized by pain and swelling of the limb, which are not specific. Numerous patients with DVT are asymptomatic.

Differential diagnoses to be considered include the following:

• Musculoskeletal conditions - Achilles tendonitis, arthritis, rupture of a Baker cyst, cellulitis
• Trauma - Muscle strain or tear, hematoma, soft-tissue injury, stress fracture
• Neurogenic conditions - Pain, swelling in a paralyzed limb
• Vascular conditions - Arterial insufficiency, peripheral occlusive disease, thromboembolism, superficial thrombophlebitis, postphlebitic syndrome, varicose veins, central venous occlusion (Budd-Chiari syndrome), dependent edema, congestive heart failure (CHF), hepatic disease, renal failure, nephritic syndrome, lymphedema

Differential Diagnoses

Baker Cyst
Budd-Chiari Syndrome
Congestive Heart Failure

Other Problems to Be Considered

Achilles tendonitis
Arthritis
Cellulitis
Muscle strain or tear
Hematoma
Soft-tissue injury
Stress fracture
Pain
Swelling in a paralyzed limb
Arterial insufficiency
Peripheral occlusive disease
Thromboembolism
Superficial thrombophlebitis
Postphlebitic syndrome
Varicose veins
Dependent edema
Hepatic disease
Renal failure
Nephritic syndrome
Lymphedema

Computed Tomography

Findings

Appearance of intraluminal thrombus

The CT finding of intraluminal thrombus is documented as a filling defect on a delayed contrast-enhanced scan.

Techniques

Spiral multidetector-row CT venography (CTV) from the popliteal fossa to the pelvis offers good diagnostic accuracy and correlation with sonographic findings. The radiation dose, cost, and scanning time, as well as the recent explosion in the number of requests for CT scanning at most hospitals, have made it prohibitive to use CT to evaluate extremity DVT alone.^48,49,50

Studies of multidetector-row CTV showed that that venous-phase scanning after arterial-phase scanning is feasible and possibly cost effective. In practice, adding indirect CTV to the now relatively standard CT pulmonary arteriography for suspected PE lead to additional diagnoses of thrombotic disease in only a few patients. However, this is an incremental increase of 15-38% of VTE diagnoses. Among patients in emergency departments, the yield is relatively low, and management is unlikely to be changed because DVT is rarely identified in the absence of PE. In the converse, in an oncology population, the addition of CTV to CT pulmonary angiography (CTPA) resulted in a 20% increase in detection of thrombotic disease. CTV showed DVT isolated to iliac or pelvic veins in 4.5%.^51,49,50

CTV is useful for evaluating for DVT versus other causes of leg swelling in patients with equivocal or negative Doppler sonographic results and for obtaining additional information in patients with known DVT before endovascular treatment. CTV reliably depicts the extent of the thrombi and underlying anatomic abnormalities, and it may help in defining the chronicity of the lesion. Increased attenuation of the thrombus (>60 HU) and an increased diameter of the vessel (>150% the diameter of the contralateral normal vein) are correlated with acuity, and they are predictors of successful CDT.

Limitations

CT requires the use of iodinated contrast agent, and some patients are allergic to this. In addition, renal insufficiency is a contraindication because of the large dose of contrast agent needed.

The radiation dose for bilateral lower-extremity CTV is 3-8 mSv (less than that of abdominal CT).

Claustrophobia, extreme patient girth, certain metallic implants, or inability to remain immobile can produce nondiagnostic studies, though these factors generally less important with CT than with MRI.

Degree of Confidence

In preliminary studies, CTV findings that were used to exclude iliofemoral thrombi had a sensitivity equivalent to that of ultrasonography. Studies in which indirect CTV was compared with venography showed 100% sensitivity and 96-97% specificity. Contrast enhancement of vessels to greater than 60 HU is desired. In the studies, CTV required 80% less contrast agent than venography.

In an ICU setting, combined CTPA and CTV yielded a 25% incidence of nondiagnostic DVT studies because of inadequate contrast opacification or because of artifacts due to metallic hardware. CT scans do not help in differentiating chronic from acute DVT.

False Positives/Negatives

False-positive findings include tumor thrombus and/or invasion (pelvis and cava), compression by extrinsic mass (usually detected), inflow defects from unopacified blood (usually seen at the iliac confluence to the IVC, brachiocephalic confluence, or inflow at the renal vein), and poorly timed CT scanning with indeterminate findings.

False-negative findings include small thrombi ( <1 cm) when CT is performed at large gaps or intervals (ie, 5 mm of every 20 mm scanned) to reduce the radiation dose. This technique reduces sensitivity as well.

Magnetic Resonance Imaging

Findings

Findings on magnetic resonance venography (MRV) depend on the sequence used. If nonenhanced (flow, bright blood) or contrast-enhanced (gadolinium-enhanced) images are obtained, they demonstrate a bright rim around a dark intraluminal filling defect.

Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Fibrosing Dermopathy. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans. 

NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see the FDA Public Health Advisory or Medscape.

Uses

Although MRI is highly sensitive and relatively specific, the cost of the examination, the technical complexity, and the lack of general availability limit the use of MRV as a screening tool. Specific indications for MRV are primarily as an alternative to CT (particularly in patients with an allergy to contrast material, in those with renal failure, and those in whom an evaluation of the iliocaval veins are required for questionable sonographic findings) or for a preinterventional evaluation of the extent of a thrombus.^52,53

Limitations

MRI cannot be used in patients with ferromagnetic implants or in those who depend on metallic devices that cannot be placed in the imaging unit.

Claustrophobia, extreme patient girth, certain metallic implants, or an inability to remain immobile can produce nondiagnostic studies.

False Positives/Negatives

MRV is effective and accurate, with sensitivity and specificity for iliac and femoral DVT approaching 100% compared with venography and a 92% sensitivity in detecting isolated calf-vein thrombus. In addition, pelvic veins that are nearly impossible to visualize on sonography and difficult to view by other means are consistently imaged well with MRV.

In general, MRI findings are subject to many artifacts that simulate vascular disease. Adjacent metallic objects, inadequate contrast enhancement, turbulent or sluggish venous blood flow, inflow from another vein into a vessel filled with contrast agent, and reflux (reversal) of venous blood flow may affect the signal received, depending on the machine and protocol chosen. False-positive findings may result from slow or turbulent flow, an adjacent pulsatile structure, or hypointense inflow defects.

Ultrasonography

Findings

Compression ultrasonography entails imaging the calf to the groin in the axial plane with a 5- to 10-MHz transducer. Compression is intermittently applied to induce complete coaptation of the walls of the patent vein. If the vein does not compress, it is occluded. Attempts to visualize iliac and pelvic veins are made.

Regarding clinical outcomes, the negative predictive value at 3 months after compression ultrasonography yields normal results is 97-98%, and greater than 99% with serial sonography. A more comprehensive study than this includes color Doppler imaging. In addition to compressibility, the evaluation includes an assessment for incomplete color filling, flow augmentation (vein patency peripheral to the transducer), and respiratory variation (patency central to the transducer). A negative single, complete duplex color sonogram of the entire lower extremity obtained to assess suspected DVT has a negative predictive value of 99.5%.

Specific findings include the following:

• Incompressibility: A thrombosed vein does not compress.
• Loss of augmentation: Loss of appropriate increased flow when the lower extremity is compressed implies an obstruction (clot) between the transducer and the compressed area.
• Visualization: DVT may be directly visualized as moderately echoic to hyperechoic masses separate from anechoic fluid.
• Doppler flow: Doppler color-flow imaging can depict absent or abnormal flow in an area where isoechoic clot might not be visible.
• Below-the-knee thrombus: A clot below the popliteal vein level remains an elusive area in duplex scanning. It is challenging to detect, and detection is operator dependent.

Indications

Ultrasonography is the current first-line imaging examination for DVT because of its relative ease of use, absence of irradiation or contrast material, and high sensitivity and specificity in institutions with experienced sonographers.

Limitations

Patient size limits the use of sonography because large patients are difficult to scan with accuracy. Good-quality sonograms depend on the experience of the technologist performing the examination. The iliac and pelvic veins are not imaged consistently with sonography.

Degree of Confidence

In patients with clinically suspected disease, compression ultrasonography is 95-99% sensitive for proximal venous thrombus compared with contrast venography. For isolated calf-vein thrombus, the sensitivity decreases below 50%. The high accuracy of ultrasonography versus venography for the diagnosis of proximal DVT has been demonstrated in asymptomatic patients. In clinical evaluations in which anticoagulation was withheld on the basis of negative serial compression sonograms, the incidence of thromboembolic complications was 0.07-1.5% at 6-month follow-up.^44,45

Because of the limitation of diagnostic study in the proximal veins, serial scans are required to ensure that calf-vein DVT is not progressing. A few become positive over 7-day follow-up. However, because of the cost and patient-compliance issues with follow-up testing, investigators evaluated the usefulness of single, complete lower-extremity compression sonography. The technical-failure rate was 1.5%; these cases required additional study. The outcome evaluated was thromboembolic complication at 3 months, which occurred in 0.2-0.8% of studies.

Visualization of iliac or proximal thrombus is often difficult. In the presence of thigh swelling or an abnormal common femoral vein, the central iliocaval veins warrant evaluation. Interposed bowel gas may compromise duplex ultrasonography, and CTV or MRV have been useful adjuncts. Visualization at the adductor canal is similarly difficult, and a focal thrombus may not be identified; however, this has not compromised the clinical relevance of a negative study. If indeterminate findings occur, extremity venography remains the diagnostic criterion standard.

False Positives/Negatives

False-positive findings may result from a technical error in scanning or from interpreting chronic DVT as acute DVT. However, the use of compression ultrasonography with a consideration of venous diameter is highly sensitive in identifying recurrence.^54,31

False-negative findings may result from inadequate scanning due to the size of the patient's leg; edema; or inexperience of the technologist, who must carefully scan each segment. In addition, iliac or pelvic DVT may be missed because of overlying bowel gas, which is the major limitation of duplex scanning in patients with DVT. In most patients, an iliac or pelvic DVT cannot be completely excluded.

Femoral vein duplication is a congenital variant that poses a pitfall in diagnosis. If a patent femoral vein is identified, an occluded duplicated vein may be missed if the anomaly is not recognized.

Nuclear Imaging

Findings

Radiolabeled peptides that bind to various components of a thrombus have been investigated. Apcitide, a technetium-labeled platelet glycoprotein IIb/IIIa receptor antagonist, is approved for diagnostic studies of DVT. Other peptides in development include fragments of fibronectin with a distinct fibrin-binding domain and analogs of laminin and thrombospondin, which bind to platelet receptors.⁵⁵

The cost of the tests and the inability to visualize the anatomy of the area of involvement (which many clinicians prefer) has lead to the underuse of scintigraphy. The radiation dose is 6.8 mSv, equivalent to lower-extremity CTV.

Degree of Confidence

Foci of increased activity indicate an acute thrombus in that location. This scanning technique is used in institutions where practitioners have experience and confidence in the technique.

A multicenter evaluation of apcitide study compared with the standard of venography in 243 symptomatic or high-risk patients revealed 75.5% sensitivity. However, after patients with a history of DVT or PE were excluded, the sensitivity and specificity were 90.6% and 83.9%, respectively, with respect to venography.⁵⁶

The suggestion of improved sensitivity for acute thrombus was supported in a subsequent study that showed a sensitivity of 92% and a specificity of 85% for differentiating between acute and chronic DVT.

Angiography

Findings

The classic finding of acute thrombus is an intraluminal filling defect in the contrast opacified vein. Lack of opacification of a vein or venous segment indicates occlusion. Occlusion is consistent with an acute or chronic thrombus. Findings of intraluminal septation, webs, or stenoses are consistent with a healed or remote DVT. In chronic DVT, recanalization can result in a linear filling defect in the vein, sometimes termed the tram-track pattern. The vein appears as if it were 2 small, paired veins.

Uses

Until the 1980s, venography was the criterion standard examination for DVT. This procedure is now uncommonly performed because of the patient's discomfort from needle puncture, the potential for infiltration of contrast agent at the injection site or allergy to the agent, and the cost in time and infrastructure necessary to perform the examination. The development of highly sensitive, noninvasive ultrasonography and impedance plethysmography protocols for DVT has relegated the use of venography to specific indications.

Venography remains the examination of choice when absolute determination of the presence and extent of thrombus is needed. This study is often required in obese patients, in patients with severe leg edema, or in patients in whom results of noninvasive tests are equivocal or negative in the setting of high clinical suspicion.

Technique

An IV line is placed in a dorsolateral foot vein, and several tourniquets (placed at the ankle and below and above the knee), or reverse Trendelenburg positioning are used to shunt contrast material into the deep venous system. The pelvis is imaged by compressing the femoral vein while the leg is elevated or while the table is moved from the reverse Trendelenburg to the Trendelenburg (head-down) position. Compression is then released while the external iliac vein is rapidly imaged.

Images are obtained from the foot to the pelvis, and detailed images of the entire deep venous system, including the paired tibial veins, iliacs, and IVC can be obtained. The internal iliac vein in the pelvis is not imaged, and a clot in this area cannot be excluded. The mean radiation dose for a single extremity is 6 mSv.

Degree of Confidence

Venography is considered the criterion standard. If technically adequate, the study offers a high degree of confidence. Technical limitations include poor IV access in the foot, poor contrast opacification of the deep veins (contrast material shunted to superficial veins, injection too slow, poor tourniquet compression), motion artifact, and excessive muscular contractions or spasms.

False Positives/Negatives

False-positive findings may result from poor filling of the deep venous system with contrast material or inadvertent injection of air bubbles. A tumor thrombus may appear as a filling defect that is not be recognized as tumor without a cross-sectional study. Extrinsic compression or compartment syndrome may cause occlusion of the vein, which may be falsely positive for thrombus.

Intervention

Image-guided therapy

Percutaneous transcatheter treatment of patients with DVT consists of thrombus removal with CDT, mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions. Patients may or may not be given PE prophylaxis by means of filter placement in the IVC. The lack of data from multicenter prospective randomized trial data regarding the safety and efficacy of these therapies complicated the decision to intervene and the choice of intervention. Problems in the existing literature are variability in patient selection and the lack of standard definitions of short- or long-term efficacy and complications. A consensus regarding indications exists, though it is based on mid-level evidence from nonrandomized controlled trials.

Goals of endovascular therapy include reducing the severity and duration of lower-extremity symptoms, preventing PE, diminishing the risk of recurrent venous thrombosis, and preventing PTS. When an invasive procedure is considered, the benefit must be weighed against the added risk compared with standard anticoagulant therapy. If it is to be performed, the intervention must improve the results of current medical therapy. The risk of PE is 2%, the risk of recurrent DVT is 4%, and the risk of major bleeding is 5%. Most difficult to discern, the risk of PTS is 45% at 2 years.

Asymptomatic DVT is not considered an indication for endovascular intervention at this time. The incidence of PTS at 5 years after asymptomatic calf or proximal DVT is low at 5%.⁵⁷ The absence of symptoms may reflect the lack of the obstructive effect that is proposed to initiate the insufficiency. Although the incidence of PTS may not warrant treatment, some reports suggest that treatment of asymptomatic DVT may be necessary to prevent most cases of PE that are diagnosed at autopsy. Asymptomatic proximal DVT had a mortality risk of 13.7% versus 2% in patients without DVT.

Catheter-directed thrombolysis

Indications

Indications for intervention include the relatively rare phlegmasia or symptomatic IVC thrombosis that responds poorly to anticoagulation alone, or symptomatic iliofemoral or femoropopliteal DVT in patients with a low risk of bleeding. In the last groups, the goal is to reduce the high risk of PTS or to achieve symptomatic relief in conjunction with angioplasty or stent placement.

Phlegmasia cerulea dolens is an indication for emergency CDT in patients with moderate or low bleeding risks. This recommendation is based on reports of limb salvage without the high rates of limb amputation and death when alternative therapies are used.⁵⁸ In patients with a high risk for hemorrhagic complications, surgical thrombectomy remains an effective option, though it often results in incomplete thrombus removal, recurrent DVT, and an increased incidence of systemic complications.

Acute or subacute IVC thrombosis that causes at least moderate pelvic congestion, limb symptoms, or compromised visceral venous drainage warrants CDT. Involvement of the suprarenal cava, renal veins, and/or hepatic veins may precipitate acute renal or hepatic failure. Thrombus that involves the upper IVC may make it impossible to place an IVC filter for PE prophylaxis.

Subacute and chronic iliofemoral DVT is accompanied by moderate-to-severe pelvic or limb symptoms with a low bleeding risk. Because of recanalization of the iliac vein is unlikely, iliofemoral DVT often produces valvular reflux. This combination of outflow obstruction and reflux is associated with the most symptomatic forms of PTS. In this situation, patients have venous damage, and the alternative is venous bypass. In these instances, CDT is seldom expected to completely clear the vein, but it is often used to remove any acute component of thrombus and to uncover chronic stenoses or underlying anatomic abnormality as an adjunct to angioplasty or stent placement. Compared with systemic thrombolysis, CDT improves the preservation of valve competence (44% vs 13%).

The indication for CDT in the relatively common event of acute iliofemoral or femoropopliteal DVT is somewhat controversial. CDT may be superior to anticoagulation with regard to decreasing the incidence of recurrent DVT and PTS. However, the evidence is not conclusive. CDT improves thrombus clearance compared with systemic thrombolysis. Few DVT resolve after heparin therapy, but systemic thrombolysis improves the rate to 30%, and CDT removes e80% of thrombi.⁵⁹ Reports of CDT for the management of acute DVT between 1994 and 2004 described anatomic and clinical success rates of 76-100%. The incidence of major hemorrhagic complications was 0-24%.

A prospective registry of 287 patients treated with a mean 53-hour urokinase (uPA) infusion showed anatomic success in 83%. About 34% of patients received adjunctive stent placement for underlying lesions. Complications of major bleeding and rethrombosis were observed in 11% and 25% of patients, respectively, at 30-day follow-up.^60,61

A randomized trial in which surgical thrombectomy with anticoagulation was compared with anticoagulation alone demonstrated the early clearance of thrombus to reduce PTS. At 10-year follow-up of the surgical versus anticoagulation cohorts, the rate of lower-extremity swelling was 18% and 71%, respectively, whereas the incidence of ulceration was 8% and 18%, respectively. Any clinical advantage for rapid clearance with CDT (similar to surgical thrombectomy) relies on a demonstration that outcomes reflect a similar reduction in the incidence of PTS, and furthermore, on a determination of whether that reduction justifies the increased incidence of major bleeding (11% vs 3% with anticoagulation).^62,63

Three studies demonstrated improved long-term venous function after CDT versus anticoagulation alone. Two showed a decrease in reflux or symptoms from 41-70% to 11-22%. In a retrospective case-control study, quality-of-life scores (including stigmata, health distress, physical function, and symptoms) were improved at 22-month follow-up after CDT with anticoagulation versus anticoagulation alone.⁶⁴

The transcatheter approach facilitates the diagnosis of predisposing anatomic lesions or anomalies. In patients with iliofemoral DVT, CDT was successful for recanalization in 92-100% of patients, and it revealed an underlying lesion in 50-66%. Treatment of these stenoses with angioplasty and stent placement reestablished unobstructed flow and achieved a prompt clinical response. Studies with 2-year follow-up documented a 5-11% incidence of valvular incompetence.

Technique

Access to the popliteal vein is usually obtained with ultrasonographic guidance, though the common femoral, tibial, or internal jugular veins are also used. When thrombolysis is planned, use of ultrasonography and a micropuncture 21-gauge needle are recommended to minimize bleeding risk. Diagnostic venography is used to identify the extent of DVT, and fluoroscopic guidance is the most accurate and straightforward means of placing infusion catheters or devices. A sheath is placed, and a multiple–side-hole catheter or wire is used to deliver the drug and maximize exposure of the lytic to the surface area of the thrombus.

Plasminogen activators include streptokinase, u-PA, tissue-type plasminogen activator (tPA), tenecteplase (TNK), and recombinant tPA (r-tPA). The US Food and Drug Administration (FDA) has approved only streptokinase for systemic thrombolytic therapy of DVT. However, this agent is not currently recommended because of high rates of allergic reaction and bleeding complications and because of the availability of lower-risk agents. uPA was used extensively in the 1980s and 1990s, but it was temporarily taken off the market, and tPA and r-tPA subsequently became the agents of choice. In a retrospective analysis of CDT for DVT, no significant differences were observed between uPA, tPA, and r-tPA with regard to success rate (>97%) or major complications (3-8%).

Recommended continuous dosages for CDT of unilateral leg DVT are tPA 0.5-1.0 mg/h, r-tPA 0.25-0.75 U/h, or TNK 0.25-0.5 mg/h. Other administration options include an initial lacing dose, which entails an initial bolus given throughout the target thrombus, and a front-loaded dose, which is a high concentration given for the first few hours. No advantage has been demonstrated for either approach.

Most practitioners use concomitant heparinization. Full heparinization was commonly used in conjunction with uPA, whereas the current trend has been to administer subtherapeutic heparin with tPA. LMWH has not been studied in this setting. In the coronary literature, enoxaparin improved outcomes (death and myocardial infarction reduced from 12 to 9.9%), but it significantly increased bleeding complications (from 1.4% to 2.1%).

During thrombolysis, patients remain on bed rest with frequent monitoring of vital signs, and puncture sites. Pericatheter oozing, enlarging hematoma, or evidence of GI-GU bleeding warrant immediate attention. Additional punctures, particularly arterial or intramuscular punctures, should be avoided. A separate IV access facilitates blood sampling to be performed at 6-hour intervals to monitor the patient's hematocrit, platelet count, activated partial thromboplastin time (aPTT, if concomitant heparinization is used), and possibly fibrinogen values. Monitoring fibrinogen levels is controversial, though levels 4.4 µmol/L ( <150 mg/dL) might indicate a clinically significant systemic effect.

Contraindications are the same as those for thrombolysis in general. Absolute contraindications include active internal bleeding or DIC, a cerebrovascular event, trauma, or neurosurgery within 3 months. Relative contraindications include major surgery within 10 days, obstetric delivery, major trauma, organ biopsy, intracranial or spinal cord tumor, uncontrolled hypertension, major GI hemorrhage (within 3 mo), serious allergic reaction to a thrombolytic agent, known right-to-left cardiac or pulmonary shunt or left-heart thrombus, and an infected venous thrombus.

Percutaneous mechanical thrombectomy devices

Percutaneous mechanical thrombectomy devices are a popular adjunct to CDT. Although these devices may not completely remove thrombus, they are effective for debulking and for minimizing the dose and time required for infusing a thrombolytic. In patients at high risk for hemorrhagic complications of thrombolysis, mechanical thrombectomy may obviate infusion. Such devices are most commonly used to initially restore antegrade flow (in cases of limb threat) or to manage a resistant thrombus identified during thrombolysis.

The most basic mechanical method for thrombectomy is thromboaspiration, or the aspiration of thrombus through a sheath. Balloon maceration of the thrombus may be done to facilitate the procedure. The most technically advanced devices, approved primarily for interventions requiring hemodialysis access, may be divided by mechanism into categories of recirculation and fragmentation. Recirculation devices engage thrombus and destroy it by continuously mixing it by creating a hydrodynamic vortex.

Fragmentation devices leave macroscopic particulate effluent and include devices that chop, brush, or cut the clot. With these devices, concomitant lytic infusion and possible IVC filter placement are necessary to ensure PE prophylaxis. With recirculation devices, only the Trellis-8 Peripheral Infusion System (Bacchus Vascular, Inc., Santa Clara, CA) is FDA approved for the treatment of DVT. The AngioJet system (Possis Medical Inc., Minneapolis, MN), has the broadest FDA-approved uses, including uses in the coronary and peripheral arteries and in obtaining arteriovenous access; this is one of the most effective devices.

Reports have described use of the Arrow-Trerotola, AngioJet (Possis Medical), and Helix percutaneous thrombectomy devices for iliofemoral DVT, combined therapy (often with adjunctive thrombolysis, angioplasty and stenting, and placement of an IVC filter with the Arrow-Trerotola). These devices had 74-100% initial technical and 24-hour clinical success rates. Complete thrombus removal was variable (23-100%). The remainder improved with lytic infusion, with a mean infusion time of 6 hours. Only 1 study had a 6% incidence of major bleeding complications. The primary patency rate at 1 year was 85%, and clinical success was obtained in 92%. At 9- to 12-month follow-up, 2 studies demonstrated an 8% rate of venous insufficiency, whereas 2 others showed repeat DVT in 15-23%.

Although the literature lacks conclusive evidence, some data support the argument that DVT treated with anticoagulation results in a high risk of PTS 5-10 years later. Active removal of the thrombus with surgery or catheter-directed lysis clears the thrombus relatively quickly and improves preservation of valvular function while reducing the incidence and severity of PTS. However, systemic or catheter-directed pharmacologic lysis entails a high risk of bleeding complications. Initial data suggest that combination therapy that includes percutaneous mechanical thrombectomy to reduce the dose and duration of lysis may achieve a level of thrombus clearance that reduces the incidence of PTS without elevating the bleeding risk.

IVC filters

In most patients with DVT, prophylaxis against the potentially fatal passage of thrombus from the lower extremity or pelvic vein to the pulmonary circulation is adequately accomplished with anticoagulation. An IVC filter is a mechanical barrier to the flow of emboli larger than 4 mm. Indications for filter placement include DVT with a contraindication to anticoagulation, major bleeding due to anticoagulation therapy, or failed anticoagulation (manifest by progressive DVT or new PE during adequate anticoagulation).

In the past, IVC filters were placed in 4.4% of patients. Recent use was documented in 14% of patients with DVT; this rate was perhaps due to broadened indications with the introduction of removable filters. Temporary or removable filters, all of which may also be left as permanent, permit transient mechanical PE prophylaxis. This option may be useful in the setting of polytrauma, head injury, hemorrhagic stroke, known VTE, or major surgery when PE prophylaxis must be maintained during a short-term contraindication to anticoagulation.

In a randomized trial, the addition of an IVC filter to anticoagulation for DVT increased the risk of recurrent DVT (11.6% to 20.8%), and it did not improve the 2-year survival rate. However, the filter group had significantly fewer PEs (1.1% vs 4.8%). Of note was the risk of major bleeding at 3 months (10.5%). This result agrees with other reports and highlights the usual trade-off of prophylaxis with a filter versus anticoagulation and the respective complication risks of new DVT (peripheral to the filter) versus major hemorrhage. In the elderly patient with an increased risk of bleeding, and particularly if the patient is at risk for trauma, the risk and benefits may favor use of a filter.

CDT does not add to the risk of PE to warrant routine filter placement. However, for patients with contraindications to pharmacologic lysis in whom a PMT device is to be used, a filter may be a useful adjunct.^60,61

Valve replacement

Percutaneously placed bioprosthetic venous valves are under development and may provide a minimally invasive therapy to the long-term complication of PTS due to valve destruction. If successful, this approach may provide a percutaneous therapeutic alternative for patients with primarily palliative options to manage their venous reflux symptoms. An effective therapy should diminish one of the primary indications for aggressive thrombolytic therapy for acute DVT.

Medicolegal Pitfalls

• False-negative misdiagnosis with embolic sequelae (eg, PE) can result in litigation. For this reason, the threshold for workup and attention to any abnormality on an otherwise normal image should be low.
• Use of thrombolytic medications to lyse DVT can cause intracranial bleeding, though this is infrequent, and death or impairment can result.
  • Careful assessment of the bleeding risk is needed before this therapy is attempted. Indications for lysis should be balanced against the possibility of bleeding before pharmacologic thrombolysis is attempted.
  • The need should be compelling when thrombolysis is considered in a setting of known contraindications. Factors such as recent surgery, stroke, GI or other bleeding, and underlying coagulopathy increase the bleeding risk when the thrombolytic medication is administered. The process of obtaining informed consent should include a discussion of these risks.
• Mechanical thrombectomy or potentially any manipulation of catheters within thrombus can cause clot migration and/or PE.
  • If a nonrecirculating device is used, the threshold for temporary filter placement is low.
  • The operator should be capable of treating massive PE if mechanical DVT thrombectomy is being performed.

Special Concerns

• The incidence of DVT is increased in women who are pregnant compared with the general population
• Diagnostic confirmation is usually performed by using ultrasonography or MRI.
• Limited radiographs with appropriate shielding can be obtained after the first trimester.
• If major DVT occurs, usual treatment is anticoagulation therapy. Treatment more aggressive than this is usually considered only after the baby is delivered.

Multimedia

Media file 1: Sequential images demonstrate treatment of iliofemoral deep venous thrombosis due to May-Thurner (Cockett) syndrome. Far left, View of the entire pelvis demonstrates iliac occlusion. Middle left, After 12 hours of catheter-directed thrombolysis, an obstruction at the left common iliac vein is evident. Middle right, After 24 hours of thrombolysis, a bandlike obstruction is seen; this is the impression made by the overlying right common iliac artery. Far left, After stent placement, image shows wide patency and rapid flow through the previously obstructed region. Note that the patient is in the prone position in all views. (Right and left are reversed.)

Media file 2: Lower-extremity venogram shows outlining of an acute deep venous thrombosis in the popliteal vein with contrast enhancement.

Media file 3: Lower-extremity venogram shows a nonocclusive chronic thrombus. The superficial femoral vein (lateral vein) has the appearance of 2 parallel veins, when in fact, it is 1 lumen containing a chronic linear thrombus. Although the chronic clot is not obstructive after it recanalizes, it effectively causes the venous valves to adhere in an open position, predisposing the patient to reflux in the involved segment.

Media file 4: Two views of a commercially available thrombectomy device. The Helix Clot Buster (Microvena Corp, Plymouth, MN) works by creating a vortex with a spinning self-contained propeller that macerates the clot. No thrombolytic agent (ie, tissue plasminogen activator) is necessary when this device is used, but adjunct thrombolytic medications can be useful. Competing devices are available from Boston Scientific, Cordis Endovascular, Possis Medical, and other manufacturers.

Media file 5: Popliteal vein thrombosis with normal compression of the common femoral vein. Image courtesy of Very Special Images with permission from Dr Lennard A. Nadalo.

Media file 6: Bilateral popliteal vein thrombosis with normal compression of the superficial femoral vein. Image courtesy of Very Special Images with permission from Dr Lennard A. Nadalo.

Media file 7: Popliteal vein thrombosis. Duplex sonogram shows absent flow. Image courtesy of Very Special Images with permission from Dr Lennard A. Nadalo.

Media file 8: Popliteal vein thrombosis. Gray-scale images show compression failure. Image courtesy of Very Special Images with permission from Dr Lennard A. Nadalo.

References

1. Useche JN, de Castro AM, Galvis GE, Mantilla RA, Ariza A. Use of US in the evaluation of patients with symptoms of deep venous thrombosis of the lower extremities. Radiographics. Oct 2008;28(6):1785-97. [Medline].

2. Chang R, Chen CC, Kam A, Mao E, Shawker TH, Horne MK 3rd. Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulation--results of pilot study. Radiology. Feb 2008;246(2):619-29. [Medline].

3. Biuckians A, Meier GH 3rd. Treatment of symptomatic lower extremity acute deep venous thrombosis: role of mechanical thrombectomy. Vascular. Sep-Oct 2007;15(5):297-303. [Medline].

4. Li W, Salanitri J, Tutton S, Dunkle EE, Schneider JR, Caprini JA, et al. Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism--preliminary experience. Radiology. Mar 2007;242(3):873-81. [Medline].

5. [Best Evidence] Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev. Oct 8 2008;CD005258. [Medline].

6. Virchow R, Chance R. Cellular Pathology. New York: Dewitt;1860.

7. Henriksen O, Sejrsen P. Effect of "vein pump" activation upon venous pressure and blood flow in human subcutaneous tissue. Acta Physiol Scand. May 1977;100(1):14-21. [Medline].

8. Wakefield TW, Strieter RM, Schaub R, et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg. Feb 2000;31(2):309-24. [Medline].

9. Wakefield TW, Proctor MC. Current status of pulmonary embolism and venous thrombosis prophylaxis. Semin Vasc Surg. Sep 2000;13(3):171-81. [Medline].

10. Kearon C. Initial treatment of venous thromboembolism. Thromb Haemost. Aug 1999;82(2):887-91. [Medline].

11. Kakkar VV, Howes J, Sharma V, et al. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost. Apr 2000;83(4):523-9. [Medline].

12. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. Mar 27 2000;160(6):761-8. [Medline].

13. Stein PD. Silent pulmonary embolism. Arch Intern Med. Jan 24 2000;160(2):145-6. [Medline].

14. Meissner MH, Caps MT, Zierler BK, et al. Deep venous thrombosis and superficial venous reflux. J Vasc Surg. Jul 2000;32(1):48-56. [Medline].

15. Meissner MH, Caps MT, Zierler BK, et al. Determinants of chronic venous disease after acute deep venous thrombosis. J Vasc Surg. Nov 1998;28(5):826-33. [Medline].

16. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg. Oct 1993;18(4):596-605; discussion 606-8. [Medline].

17. Caps MT, Manzo RA, Bergelin RO, et al. Venous valvular reflux in veins not involved at the time of acute deep vein thrombosis. J Vasc Surg. Nov 1995;22(5):524-31. [Medline].

18. Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. J Vasc Surg. Feb 1995;21(2):307-12; discussion 313. [Medline].

19. Johnson BF, Manzo RA, Bergelin RO, et al. The site of residual abnormalities in the leg veins in long-term follow- up after deep vein thrombosis and their relationship to the development of the post-thrombotic syndrome. Int Angiol. Mar 1996;15(1):14-9. [Medline].

20. Haenen JH, Wollersheim H, Janssen MC, et al. Evolution of deep venous thrombosis: a 2-year follow-up using duplex ultrasound scan and strain-gauge plethysmography. J Vasc Surg. Oct 2001;34(4):649-55. [Medline].

21. Andriopoulos A, Wirsing P, Botticher R. Results of iliofemoral venous thrombectomy after acute thrombosis: report on 165 cases. J Cardiovasc Surg (Torino). Mar-Apr 1982;23(2):123-4. [Medline].

22. Zheng Y, Zhou B, Pu X. [Frequency of protein C polymorphisms in Chinese population and thrombotic patients]. Zhonghua Yi Xue Za Zhi. Mar 1998;78(3):210-2. [Medline].

23. Juhan C, Alimi Y, Di Mauro P, et al. Surgical venous thrombectomy. Cardiovasc Surg. Oct 1999;7(6):586-90. [Medline].

24. Saarinen J, Kallio T, Lehto M, et al. The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study. J Cardiovasc Surg (Torino). Jun 2000;41(3):441-6. [Medline].

25. Elliott G. Thrombolytic therapy for venous thromboembolism. Curr Opin Hematol. Sep 1999;6(5):304-8. [Medline].

26. Baker WF Jr. Diagnosis of deep venous thrombosis and pulmonary embolism. Med Clin North Am. May 1998;82(3):459-76. [Medline].

27. Gorman WP, Davis KR, Donnelly R. ABC of arterial and venous disease. Swollen lower limb-1: general assessment and deep vein thrombosis. BMJ. May 27 2000;320(7247):1453-6. [Medline].

28. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med. Jan 24 2000;160(2):159-64. [Medline].

29. Zidane M, Schram MT, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med. Aug 14-28 2000;160(15):2369-73. [Medline].

30. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med. 2000;51:169-85. [Medline].

31. Prandoni P, Mannucci PM. Deep-vein thrombosis of the lower limbs: diagnosis and management. Baillieres Best Pract Res Clin Haematol. Sep 1999;12(3):533-54. [Medline].

32. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. Feb 1 2000;132(3):227-32. [Medline].

33. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. Jun 6 2000;132(11):853-61. [Medline].

34. Arfvidsson B, Eklof B, Kistner RL, et al. Risk factors for venous thromboembolism following prolonged air travel. Coach class thrombosis. Hematol Oncol Clin North Am. Apr 2000;14(2):391-400, ix. [Medline].

35. Slipman CW, Lipetz JS, Jackson HB, et al. Deep venous thrombosis and pulmonary embolism as a complication of bed rest for low back pain. Arch Phys Med Rehabil. Jan 2000;81(1):127-9. [Medline].

36. Ruggeri M, Tosetto A, Castaman G, Rodeghiero F. Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis. Lancet. Feb 10 2001;357(9254):441. [Medline].

37. Hamoud S, Nitecky S, Engel A, et al. Hypoplasia of the inferior vena cava with azygous continuation presenting as recurrent leg deep vein thrombosis. Am J Med Sci. Jun 2000;319(6):414-6. [Medline].

38. Greenfield LJ, Proctor MC. The percutaneous greenfield filter: outcomes and practice patterns. J Vasc Surg. Nov 2000;32(5):888-93. [Medline].

39. Tsuji Y, Goto A, Hara I, et al. Renal cell carcinoma with extension of tumor thrombus into the vena cava: surgical strategy and prognosis. J Vasc Surg. Apr 2001;33(4):789-96. [Medline].

40. Motykie GD, Caprini JA, Arcelus JI, et al. Risk factor assessment in the management of patients with suspected deep venous thrombosis. Int Angiol. Mar 2000;19(1):47-51. [Medline].

41. Motykie GD, Zebala LP, Caprini JA, et al. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis. Apr 2000;9(3):253-62. [Medline].

42. Ho CH, Chau WK, Hsu HC, et al. Causes of venous thrombosis in fifty Chinese patients. Am J Hematol. Feb 2000;63(2):74-8. [Medline].

43. Vandenbrouke JP, Bloemenkamp KW, Rosendaal FR, et al. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. BMJ. Jan 1 2000;320(7226):57-8. [Medline].

44. Lensing AW. Anticoagulation in acute ischaemic stroke: deep vein thrombosis prevention and long-term stroke outcomes. Blood Coagul Fibrinolysis. Aug 1999;10 Suppl 2:S123-7. [Medline].

45. Lensing AW, Prins MH. Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis?. Thromb Haemost. Dec 1999;82(6):1564-6. [Medline].

46. Burke DT. Prevention of deep venous thrombosis: overview of available therapy options for rehabilitation patients. Am J Phys Med Rehabil. Sep-Oct 2000;79(5 Suppl):S3-8. [Medline].

47. Merli GJ. Prophylaxis for deep venous thrombosis and pulmonary embolism in the surgical patient. Clin Cornerstone. 2000;2(4):15-28. [Medline].

48. Cham MD, Yankelevitz DF, Shaham D, et al. Deep venous thrombosis: detection by using indirect CT venography. The Pulmonary Angiography-Indirect CT Venography Cooperative Group. Radiology. Sep 2000;216(3):744-51. [Medline].

49. Loud PA, Katz DS, Bruce DA. Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology. May 2001;219(2):498-502. [Medline].

50. Loud PA, Katz DS, Klippenstein DL, et al. Combined CT venography and pulmonary angiography in suspected thromboembolic disease: diagnostic accuracy for deep venous evaluation. AJR Am J Roentgenol. Jan 2000;174(1):61-5. [Medline].

51. Coche EE, Hamoir XL, Hammer FD, et al. Using dual-detector helical CT angiography to detect deep venous thrombosis in patients with suspicion of pulmonary embolism: diagnostic value and additional findings. AJR Am J Roentgenol. Apr 2001;176(4):1035-9. [Medline].

52. Michiels JJ, Oortwijn WJ, Naaborg R. Exclusion and diagnosis of deep vein thrombosis by a rapid ELISA D- dimer test, compression ultrasonography, and a simple clinical model. Clin Appl Thromb Hemost. Jul 1999;5(3):171-80. [Medline].

53. Nawaz S, Chan P, Ireland S. Suspected deep vein thrombosis: a management algorithm for the accident and emergency department. J Accid Emerg Med. Nov 1999;16(6):440-2. [Medline].

54. Prandoni P, Bernardi E, Bagatella P, et al. The optimal treatment of venous thrombosis: current status and future perspectives. Clin Lab. 2001;47(3-4):151-4. [Medline].

55. Knight LC, Baidoo KE, Romano JE, et al. Imaging pulmonary emboli and deep venous thrombi with 99mTc-bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med. Jun 2000;41(6):1056-64. [Medline].

56. Taillefer R, Edell S, Innes G, et al. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. J Nucl Med. Jul 2000;41(7):1214-23. [Medline].

57. Ginsberg JS, Turkstra F, Buller HR, et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross- sectional study. Arch Intern Med. Mar 13 2000;160(5):669-72. [Medline].

58. Eklof B, Arfvidsson B, Kistner RL, et al. Indications for surgical treatment of iliofemoral vein thrombosis. Hematol Oncol Clin North Am. Apr 2000;14(2):471-82. [Medline].

59. Grossman C, McPherson S. Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. AJR Am J Roentgenol. Mar 1999;172(3):667-72. [Medline].

60. Mewissen MW, Seabrook GR, Meissner MH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999;211:39-49.

61. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. Apr 1999;211(1):39-49. [Medline].

62. Breddin HK. Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery. Semin Thromb Hemost. 1999;25 Suppl 3:83-9. [Medline].

63. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol. Oct 2000;36(4):1336-43. [Medline].

64. Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg. Jul 2000;32(1):130-7. [Medline].

65. Abendschein DR, Baum PK, Martin DJ, et al. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. May 2000;35(5):796-805. [Medline].

66. Adamczuk Y, Iglesias Varela ML, Forastiero R, et al. Factor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population. Thromb Haemost. Mar 2000;83(3):509-10. [Medline].

67. Ageno W. Treatment of venous thromboembolism. Thromb Res. Jan 1 2000;97(1):V63-72. [Medline].

68. Agnelli G, Sonaglia F. Prevention of venous thromboembolism. Thromb Res. Jan 1 2000;97(1):V49-62. [Medline].

69. Akar N, Akar E, Yilmaz E. Factor V (His 1299 Arg) in Turkish patients with venous thromboembolism. Am J Hematol. Feb 2000;63(2):102-3. [Medline].

70. Aki Z, Kotiloglu G, Ozyilkan O. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. Am J Gastroenterol. Apr 2000;95(4):1093-4. [Medline].

71. Andrew WK. An unusual cause of deep venous thrombosis of the lower limb. S Afr Med J. Jan 2000;90(1):42. [Medline].

72. Ansari A. Rapid lysis of deep vein thrombosis by low molecular weight heparin. Tex Heart Inst J. 2000;27(1):74-5. [Medline].

73. Arnaud E, Nicaud V, Poirier O, et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol. Feb 2000;20(2):585-92. [Medline].

74. Badgett DK, Comerota MC, Khan MN, et al. Duplex venous imaging: role for a comprehensive lower extremity examination. Ann Vasc Surg. Jan 2000;14(1):73-6. [Medline].

75. Barrellier MT, Le Hello C, Verfaille M, et al. [Echo-doppler monitoring of asymptomatic distal deep vein thrombosis in patients given low-molecular-weight-heparin at prophylactic doses after orthopedic surgery]. J Mal Vasc. Jun 2000;25(3):195-200. [Medline].

76. Bauer KA. Venous thromboembolism in malignancy. J Clin Oncol. Sep 2000;18(17):3065-7. [Medline].

77. Beauchamp NJ, Makris M, Preston FE, et al. Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency--partial/complete deletions and rearrangement of the antithrombin gene. Thromb Haemost. May 2000;83(5):715-21. [Medline].

78. Benton L. DVT prevention. Low-molecular-weight heparin is a viable option. Am J Nurs. Feb 2000;100(2):84. [Medline].

79. Bertina RM. Protein C deficiency and venous thrombosis--the search for the second genetic defect. Thromb Haemost. Mar 2000;83(3):360-1. [Medline].

80. Bigaroni A, Perrier A, Bounameaux H. Is clinical probability assessment of deep vein thrombosis by a score really standardized?. Thromb Haemost. May 2000;83(5):788-9. [Medline].

81. Bigaroni A, Perrier A, de Moerloose P, et al. Risk of major bleeding in unselected patients with venous thromboembolism. Blood Coagul Fibrinolysis. Mar 2000;11(2):199-202. [Medline].

82. Bjorgell O, Nilsson PE, Benoni G, et al. Symptomatic and asymptomatic deep vein thrombosis after total hip replacement. Differences in phlebographic pattern, described by a scoring of the thrombotic burden. Thromb Res. Sep 1 2000;99(5):429-38. [Medline].

83. Bjorgell O, Nilsson PE, Jarenros H. Isolated nonfilling of contrast in deep leg vein segments seen on phlebography, and a comparison with color Doppler ultrasound, to assess the incidence of deep leg vein thrombosis. Angiology. Jun 2000;51(6):451-61. [Medline].

84. Bjorgell O, Nilsson PE, Nilsson JA, et al. Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost. May 2000;83(5):648-51. [Medline].

85. Blaivas M, Lambert MJ, Harwood RA, et al. Lower-extremity Doppler for deep venous thrombosis--can emergency physicians be accurate and fast?. Acad Emerg Med. Feb 2000;7(2):120-6. [Medline].

86. Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect?. Br J Haematol. Jan 2000;108(1):191-3. [Medline].

87. Blattler W, Kreis N, Blattler IK. Practicability and quality of outpatient management of acute deep venous thrombosis. J Vasc Surg. Nov 2000;32(5):855-60. [Medline].

88. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. Jan 10 2000;160(1):49-52. [Medline].

89. Blombery P, McGrath B. Chronic venous insufficiency in post-thrombotic patients. Clin Sci (Colch). Apr 2000;98(4):445-7. [Medline].

90. Blum JE, Handmaker H. 1999 plenary session: Friday imaging symposium: role of small-peptide radiopharmaceuticals in the evaluation of deep venous thrombosis. Radiographics. Jul-Aug 2000;20(4):1187-93. [Medline].

91. Bodner LJ, Nosher JL, Patel KM, et al. Peripheral venous access ports: outcomes analysis in 109 patients. Cardiovasc Intervent Radiol. May-Jun 2000;23(3):187-93. [Medline].

92. Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol. Jan-Feb 2000;22(1):66-72. [Medline].

93. Bookstein JJ, Bookstein FL. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude. J Vasc Interv Radiol. Mar 2000;11(3):299-303. [Medline].

94. Botella FG, Labios Gomez M, Braso Aznar JV. [Deep venous thrombosis: present and future]. Med Clin (Barc). Apr 22 2000;114(15):584-96. [Medline].

95. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet. Jul 15 2000;356(9225):182-3. [Medline].

96. Breen P. DVT. What every nurse should know. RN. Apr 2000;63(4):58-62; quiz 63. [Medline].

97. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. May 2000;83(5):693-7. [Medline].

98. Brill-Edwards P, Lee A. D-dimer testing in the diagnosis of acute venous thromboembolism. Thromb Haemost. Aug 1999;82(2):688-94. [Medline].

99. Burbridge BE, Wallace JK, Rajput A, et al. Doppler ultrasonographic examination of the leg veins of patients with Parkinson disease. J Psychiatry Neurosci. Sep 1999;24(4):338-40. [Medline].

100. Burke B, Kumar R, Vickers V, et al. Deep vein thrombosis after lower limb amputation. Am J Phys Med Rehabil. Mar-Apr 2000;79(2):145-9. [Medline].

101. Bussey HI. Venous thromboembolism in the elderly: introduction and overview. J Thromb Thrombolysis. Jan 2000;9(1):111-2. [Medline].

102. Caliezi C, Reber G, Lammle B, et al. Agreement of D-dimer results measured by a rapid ELISA (VIDAS) before and after storage during 24h or transportation of the original whole blood samples. Thromb Haemost. Jan 2000;83(1):177-8. [Medline].

103. Caps MT, Meissner MH, Tullis MJ, et al. Venous thrombus stability during acute phase of therapy. Vasc Med. 1999;4(1):9-14. [Medline].

104. Carter AM, Catto AJ, Kohler HP, et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. Aug 1 2000;96(3):1177-9. [Medline].

105. Casserly LF, Reddy SM, Dember LM. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis. Aug 2000;36(2):405-11. [Medline].

106. Castaman G, Tosetto A, Cappellari A, et al. The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency. Blood Coagul Fibrinolysis. Jun 2000;11(4):321-6. [Medline].

107. Chenu E, Guias B, Mottier D, et al. [What investigations should be done following the first episode of pulmonary embolism?]. Rev Mal Respir. Nov 1999;16(5 Pt 2):1007-17. [Medline].

108. Chouhan VD, Comerota AJ, Sun L, et al. Inhibition of tissue factor pathway during intermittent pneumatic compression: A possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol. Nov 1999;19(11):2812-7. [Medline].

109. Chunilal SD, Ginsberg JS. Strategies for the diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Res. Jan 1 2000;97(1):V33-48. [Medline].

110. Church V. Staying on guard for DVT & PE. Nursing. Feb 2000;30(2):34-42; quiz 43-4. [Medline].

111. Clement DL. Management of venous edema: insights from an international task force. Angiology. Jan 2000;51(1):13-7. [Medline].

112. Cohen A, Quinlan D. PEP trial. Pulmonary Embolism Prevention. Lancet. Jul 15 2000;356(9225):247; discussion 250-1. [Medline].

113. Cohen AT. Prevention of deep vein thrombosis after hip replacement. Thromb Haemost. Jan 2000;83(1):171. [Medline].

114. Cohen AT, Gallus AS, Haas S, et al. Workshop I: The potential role of new therapies in deep vein thrombosis prophylaxis. Blood Coagul Fibrinolysis. Aug 1999;10 Suppl 2:S99-102. [Medline].

115. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. Jul 1999;81(7):932-40. [Medline].

116. Conroy JM, Trivedi G, Sovd T, et al. The allele frequency of mutations in four genes that confer enhanced susceptibility to venous thromboembolism in an unselected group of New York State newborns. Thromb Res. Aug 15 2000;99(4):317-24. [Medline].

117. Corral J, Gonzalez-Conejero R, Iniesta JA, et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica. Mar 2000;85(3):293-7. [Medline].

118. D''Souza R, Guillebaud J. Venous thromboembolism and oral contraceptives. Lancet. Oct 23 1999;354(9188):1469; discussion 1469-70. [Medline].

119. Dahl OE, Frostick SP, Hull RD. Thromboembolism--an academic concern or a clinical reality?. Acta Orthop Scand. Aug 1999;70(4):404-6. [Medline].

120. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. Feb 2000;71(1):47-50. [Medline].

121. Dahlback B. Blood coagulation. Lancet. May 6 2000;355(9215):1627-32. [Medline].

122. Dai G, Gertler JP, Kamm RD. The effects of external compression on venous blood flow and tissue deformation in the lower leg. J Biomech Eng. Dec 1999;121(6):557-64. [Medline].

123. Dalsing MC, Raju S, Wakefield TW, et al. A multicenter, phase I evaluation of cryopreserved venous valve allografts for the treatment of chronic deep venous insufficiency. J Vasc Surg. Nov 1999;30(5):854-64. [Medline].

124. Daniel KR, Jackson RE, Kline JA. Utility of lower extremity venous ultrasound scanning in the diagnosis and exclusion of pulmonary embolism in outpatients. Ann Emerg Med. Jun 2000;35(6):547-54. [Medline].

125. Davidson BL. Controversies in pulmonary embolism and deep venous thrombosis. Am Fam Physician. Nov 1 1999;60(7):1969-80. [Medline].

126. Davidson BL. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis. Semin Thromb Hemost. 1999;25 Suppl 3:107-12. [Medline].

127. De Groot CJ, Bloemenkamp KW, Duvekot EJ, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol. Oct 1999;181(4):975-80. [Medline].

128. De Maeseneer MG, Tielliu IF, Tjalma WA, et al. Lack of compressibility of the common femoral vein: an unequivocal sign of proximal deep venous thrombosis on duplex ultrasound?. Cardiovasc Surg. Jun 2000;8(4):289-91. [Medline].

129. De Mitrio V, Marino R, Scaraggi FA, et al. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. Blood Coagul Fibrinolysis. Oct 1999;10(7):409-16. [Medline].

130. de Moerloose P. Diagnosis of venous thromboembolism by a rapid ELISA D-dimer test, clinical model and noninvasive imaging techniques. Clin Appl Thromb Hemost. Oct 1999;5(4):221-2. [Medline].

131. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. Sep 9 1999;341(11):801-6. [Medline].

132. De Stefano V, Zappacosta B, Persichilli S, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol. Aug 1999;106(2):564-8. [Medline].

133. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. Aug 1999;82(2):673-83. [Medline].

134. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. Mar 2000;31(3):587-91. [Medline].

135. Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. Dec 11-25 2000;160(22):3431-6. [Medline].

136. Douketis JD, Gordon M, Johnston M, et al. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res. Jul 1 2000;99(1):25-34. [Medline].

137. Dulicek P, Maly J, Safarova M. Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian region. Clin Appl Thromb Hemost. Apr 2000;6(2):87-9. [Medline].

138. Dupuy DE. 1999 plenary session: Friday imaging symposium : venous US of lower- extremity deep venous thrombosis: when is US insufficient?. Radiographics. Jul-Aug 2000;20(4):1195-200. [Medline].

139. Eekhoff EM, Rosendaal FR, Vandenbroucke JP, et al. Minor events and the risk of deep venous thrombosis. Thromb Haemost. Mar 2000;83(3):408-11. [Medline].

140. Egermayer P. Clinical model for management of pulmonary embolism. Ann Intern Med. Sep 21 1999;131(6):475. [Medline].

141. Eggum R, Lie B, Stavis P. [Phlegmasia cerulea dolens as the initial symptom of abdominal aortic aneurysm]. Tidsskr Nor Laegeforen. Dec 10 1999;119(30):4460-1. [Medline].

142. Eichinger S, Weltermann A, Philipp K, et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost. Oct 1999;82(4):1232-6. [Medline].

143. Eikelboom JW, Baker RI. Prothrombin 20210A and familial thrombophilia. Blood Coagul Fibrinolysis. Dec 1999;10(8):523. [Medline].

144. Eitzman DT, Westrick RJ, Nabel EG, et al. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. Jan 15 2000;95(2):577-80. [Medline].

145. Ellis MH, Manor Y, Witz M. Risk factors and management of patients with upper limb deep vein thrombosis. Chest. Jan 2000;117(1):43-6. [Medline].

146. Ergul SM, Rocha Lima CS, Farber JM. Abdominal venous thrombosis with prothrombin gene mutation. Am J Hematol. Feb 2000;63(2):106-7. [Medline].

147. Ertem D, Acar Y, Arat C, et al. Thrombotic and thrombocytopenic complications secondary to hepatitis A infection in children. Am J Gastroenterol. Dec 1999;94(12):3653-5. [Medline].

148. Estrada CA, McElligott J, Dolezal JM, et al. Asymptomatic patients at high risk for deep venous thrombosis who receive inadequate prophylaxis should be screened. South Med J. Dec 1999;92(12):1145-50. [Medline].

149. Ettingshausen CE, Saguer IM, Kreuz W. Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy. Eur J Pediatr. Dec 1999;158 Suppl 3:S180-2. [Medline].

150. Evans GD, Langdown J, Brown K, et al. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population. Thromb Haemost. Mar 2000;83(3):511. [Medline].

151. Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol. Jun 2000;49(6):580-90. [Medline].

152. Farmer RD, Lawrenson RA, Todd JC, et al. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database. Hum Reprod Update. Nov-Dec 1999;5(6):688-706. [Medline].

153. Few JW, Marcus JR, Placik OJ. Deep vein thrombosis prophylaxis in the moderate- to high-risk patient undergoing lower extremity liposuction. Plast Reconstr Surg. Jul 1999;104(1):309-10. [Medline].

154. Fishman EK, Horton KM. CT of suspected pulmonary embolism: study design optimization. AJR Am J Roentgenol. Oct 2000;175(4):1002-3. [Medline].

155. Flamholz R, Jeon HR, Baron JM, et al. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis. 2000;15(3):169-72. [Medline].

156. Forbes CD. A protocol for deep vein thrombosis. Practitioner. Apr 2000;244(1609):365-9. [Medline].

157. Forman HP. When is an examination complete? Lessons to be learned from cost- effectiveness analysis. Acad Radiol. Feb 2000;7(2):65-6. [Medline].

158. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. Apr 2000;161(4 Pt 1):1109-14. [Medline].

159. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. Jul 2000;82-A(7):929-38. [Medline].

160. Frenkel EP, Bick RL. Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. Semin Thromb Hemost. 1999;25(4):375-86. [Medline].

161. Freyburger G, Trillaud H, Labrouche S, et al. Rapid ELISA D-dimer testing in the exclusion of venous thromboembolism in hospitalized patients. Clin Appl Thromb Hemost. Apr 2000;6(2):77-81. [Medline].

162. Galli M, Finazzi G, Duca F, et al. The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol. Mar 2000;108(4):865-70. [Medline].

163. Garg K, Kemp JL, Wojcik D, et al. Thromboembolic disease: comparison of combined CT pulmonary angiography and venography with bilateral leg sonography in 70 patients. AJR Am J Roentgenol. Oct 2000;175(4):997-1001. [Medline].

164. Gattorno M, Molinari AC, Buoncompagni A, et al. Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupus erythematosus. Eur J Pediatr. Mar 2000;159(3):211-4. [Medline].

165. Gaustadnes M, Rudiger N, Moller J, et al. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis. Jul 1999;10(5):251-9. [Medline].

166. Gaustadnes M, Rudiger N, Rasmussen K, et al. Familial thrombophilia associated with homozygosity for the cystathionine beta-synthase 833T-->C mutation. Arterioscler Thromb Vasc Biol. May 2000;20(5):1392-5. [Medline].

167. Geroulakos G, Hossain J, Tran T. Economy-class syndrome presenting as phlegmasia caerulea dolens. Eur J Vasc Endovasc Surg. Jul 2000;20(1):102-4. [Medline].

168. Giordano P, De Lucia D, Coppola B, et al. Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report. Acta Haematol. 1999;102(2):101-3. [Medline].

169. Girard P. [Inferior vena cava interruption. How and when?]. Rev Mal Respir. Nov 1999;16(5 Pt 2):975-84. [Medline].

170. Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. Oct 1999;116(4):903-8. [Medline].

171. Girolami A, Prandoni P, Zanon E, et al. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis. Dec 1999;10(8):455-7. [Medline].

172. Girolami A, Simioni P, Girolami B, et al. Low incidence of venous thrombosis in homozygous patients with NT 20210 G to a prothrombin polymorphism. Clin Appl Thromb Hemost. Oct 1999;5(4):205-7. [Medline].

173. Girolami A, Simioni P, Scarano L, et al. Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it. J Thromb Thrombolysis. Apr 2000;9(3):271-5. [Medline].

174. Girolami A, Simioni P, Tormene D. APC resistance, oral contraceptive therapy and deep vein thrombosis: settled and unsettled problems. Haematologica. Mar 2000;85(3):225-6. [Medline].

175. Girolami A, Simioni P, Tormene D, et al. Two additional homozygous patients for the 20210 prothrombin polymorphism with no venous thrombosis. Thromb Res. Dec 1 1999;96(5):415-7. [Medline].

176. Goldberg A. Prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. Mar 2000;82(2):304-5. [Medline].

177. Goldhaber SZ. Diagnosis of deep venous thrombosis. Clin Cornerstone. 2000;2(4):29-37. [Medline].

178. Goldhaber SZ. Management of deep venous thrombosis and pulmonary embolism. Clin Cornerstone. 2000;2(4):47-58; quiz 59-64. [Medline].

179. Goldhaber SZ. The perils of D-dimer in the medical intensive care unit. Crit Care Med. Feb 2000;28(2):583-4. [Medline].

180. Goldhaber SZ. Venous thromboembolism prophylaxis in medical patients. Thromb Haemost. Aug 1999;82(2):899-901. [Medline].

181. Gonzalez Ordonez AJ, Fernandez Carreira JM, Alvarez MV, et al. A high factor II/Factor X functional ratio is not a useful predictor of the FII G20210A gene mutation in thromboembolic patients undergoing oral anticoagulant treatment. Clin Chem. Jun 2000;46(6 Pt 1):886-7. [Medline].

182. Gonzalez-Conejero R, Lozano ML, Corral J, et al. The TFPI 536C-->T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost. May 2000;83(5):787-8. [Medline].

183. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. Aug 1999;30(2):283-92. [Medline].

184. Gonze MD, Salartash K, Sternbergh WC 3rd, et al. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation. Jun 6 2000;101(22):2658-61. [Medline].

185. Goodman LR. 1999 plenary session: Friday imaging symposium : CT diagnosis of pulmonary embolism and deep venous thrombosis. Radiographics. Jul-Aug 2000;20(4):1201-5. [Medline].

186. Gotthardt M, Brandt D, Kuni H, et al. Venous bypass after deep venous thrombosis visible on an early-phase bone scan. Clin Nucl Med. Apr 2000;25(4):291-2. [Medline].

187. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. May 2 2000;132(9):689-96. [Medline].

188. Grandas OH, Klar M, Goldman MH, et al. Deep venous thrombosis in the pediatric trauma population: an unusual event: report of three cases. Am Surg. Mar 2000;66(3):273-6. [Medline].

189. Grau E, Real E, Medrano J, et al. Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting. Thromb Res. Dec 1 1999;96(5):335-41. [Medline].

190. Greaves M, Cohen H, MacHin SJ, et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. Jun 2000;109(4):704-15. [Medline].

191. Greenfield LJ, Proctor MC, Michaels AJ, et al. Prophylactic vena caval filters in trauma: the rest of the story. J Vasc Surg. Sep 2000;32(3):490-5; discussion 496-7. [Medline].

192. Grigg AP. Deep venous thrombosis as the presenting feature in a patient with coeliac disease and homocysteinaemia. Aust N Z J Med. Aug 1999;29(4):566-7. [Medline].

193. Guirguis N, Budisavljevic MN, Self S, et al. Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation. Ann Clin Lab Sci. Jan 2000;30(1):75-8. [Medline].

194. Guis-Sabatier S, Roudier J, Arnoux D, et al. Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis. Joint Bone Spine. 2000;67(2):134-6. [Medline].

195. Haas S. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Semin Thromb Hemost. 1999;25 Suppl 3:101-5. [Medline].

196. Haas S, Agnelli G, Arcelus JI, et al. Workshop II: The future of prolonged thromboprophylaxis. Blood Coagul Fibrinolysis. Aug 1999;10 Suppl 2:S103-6. [Medline].

197. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. Apr 1 2000;355(9210):1155-6. [Medline].

198. Halbmayer WM, Kalhs T, Haushofer A, et al. Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation. Blood Coagul Fibrinolysis. Jul 1999;10(5):297-302. [Medline].

199. Hamulyak K, van der Graaf F, Janssen MC, et al. Exclusion of deep vein thrombosis with rapid ELISA D-dimer testing: from theory to daily practice. Clin Appl Thromb Hemost. Oct 1999;5(4):216-9. [Medline].

200. Handoll HH, Farrar MJ, McBirnie J, et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev. 2000;(2):CD000305. [Medline].

201. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. Mar 27 2000;160(6):769-74. [Medline].

202. Harris M, Grange J. Management of calf deep venous thrombosis. Ann Emerg Med. Jun 2000;35(6):629. [Medline].

203. Hashimoto K, Shizusawa Y, Shimoya K, et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod. Jul 1999;14(7):1872-4. [Medline].

204. Heinze KG. Molecular risk factors for thrombosis and risk factors in venous thrombotic disease. Clin Lab. 2000;46(3-4):191-4. [Medline].

205. Heller C, Becker S, Scharrer I, et al. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr. Dec 1999;158 Suppl 3:S117-21. [Medline].

206. Hepner M, Roldan A, Pieroni G, et al. Factor V Leiden mutation in the Argentinian population. Thromb Haemost. Jun 1999;81(6):989. [Medline].

207. Heron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med. Feb 14 2000;160(3):382-6. [Medline].

208. Heron E, Lozinguez O, Emmerich J, et al. Long-term sequelae of spontaneous axillary-subclavian venous thrombosis. Ann Intern Med. Oct 5 1999;131(7):510-3. [Medline].

209. Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med. Mar 6 2001;134(5):409-17. [Medline].

210. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study. Thromb Haemost. Oct 1999;82(4):1218-21. [Medline].

211. Holmstrom M, Aberg W, Lockner D, et al. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis. Thromb Haemost. Oct 1999;82(4):1222-6. [Medline].

212. Horne MK 3rd, Chang R. Thrombolytic therapy for deep venous thrombosis?. JAMA. Dec 8 1999;282(22):2164-6. [Medline].

213. Horton MG, Mewissen MW, Rilling WS, et al. Hemodialysis catheter placement directly into occluded central vein segments: a technical note. J Vasc Interv Radiol. Sep 1999;10(8):1059-62. [Medline].

214. Houry D, Southall J, Manning M, et al. Use of the Amplatz thrombectomy device for severe deep venous thrombosis. South Med J. Sep 1999;92(9):915-7. [Medline].

215. Hovanessian HC. New-generation anticoagulants: the low molecular weight heparins. Ann Emerg Med. Dec 1999;34(6):768-79. [Medline].

216. Huang A, Barber N, Northeast A. Deep vein thrombosis prophylaxis protocol--needs active enforcement. Ann R Coll Surg Engl. Jan 2000;82(1):69-70. [Medline].

217. Hull RD, Pineo GF. Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis. Dec 1999;29 Suppl S1:23-31. [Medline].

218. Hull RD, Pineo GF. Long term outpatient prophylaxis for venous thromboembolism. Semin Thromb Hemost. 1999;25 Suppl 3:91-5. [Medline].

219. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out- of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. Jul 24 2000;160(14):2208-15. [Medline].

220. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double- blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med. Jul 24 2000;160(14):2199-207. [Medline].

221. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. Sep 2000;18(17):3078-83. [Medline].

222. Ihle J, Kummerle-Deschner J, Orlikowsky T, et al. Factor V Leiden and venous thrombosis in a 4-yr-old girl with Behcet''s syndrome. Rheumatology (Oxford). Feb 2000;39(2):209-10. [Medline].

223. Imanaka S, Aihara S, Yoshihara K, et al. Use of a temporary caval filter in a young man with pulmonary embolism to prevent migration of massive caval thrombus during an attempt of caval thrombolysis. J Atheroscler Thromb. 2000;6(1):18-21. [Medline].

224. Isotalo PA, Donnelly JG. Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis. Mol Diagn. Mar 2000;5(1):59-66. [Medline].

225. Jay SJ. Risk factors for thromboembolism. Ann Intern Med. Nov 16 1999;131(10):790; discussion 790-1. [Medline].

226. Jick H. Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed. BMJ. Jan 1 2000;320(7226):57; discussion 57-8. [Medline].

227. Joynt GM, Kew J, Gomersall CD, et al. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest. Jan 2000;117(1):178-83. [Medline].

228. Kamphuisen PW, Rosendaal FR, Eikenboom JC, et al. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol. May 2000;20(5):1382-6. [Medline].

229. Kaper RF, Norpoth T, Rekers H. Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism. Eur J Contracept Reprod Health Care. Mar 2000;5(1):1-15. [Medline].

230. Keeling DM, Wright M, Baker P, et al. D-dimer for the exclusion of venous thromboembolism: comparison of a new automated latex particle immunoassay (MDA D-dimer) with an established enzyme-linked fluorescent assay (VIDAS D-dimer). Clin Lab Haematol. Oct 1999;21(5):359-62. [Medline].

231. Kelsey LJ, Fry DM, VanderKolk WE. Thrombosis risk in the trauma patient. Prevention and treatment. Hematol Oncol Clin North Am. Apr 2000;14(2):417-30. [Medline].

232. Kennedy JG, Soffe KE, Rogers BW, et al. Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin. J Trauma. Feb 2000;48(2):268-72. [Medline].

233. Kesteven PL. Traveller''s thrombosis. Thorax. Aug 2000;55 Suppl 1:S32-6. [Medline].

234. Khoury A, Mosheiff R, Liebergall M. [Thromboembolism in orthopedic trauma]. Harefuah. Dec 1 1999;137(11):515-20, 592. [Medline].

235. Kim HM, Kuntz KM, Cronan JJ. Optimal management strategy for use of compression US for deep venous thrombosis in symptomatic patients: a cost-effectiveness analysis. Acad Radiol. Feb 2000;7(2):67-76. [Medline].

236. Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am. Nov 2001;19(4):839-59. [Medline].

237. Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian- Americans. Am J Cardiol. Jun 1 2000;85(11):1334-7. [Medline].

238. Knofler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines. Eur J Pediatr. Dec 1999;158 Suppl 3:S147-50. [Medline].

239. Koch HG, Nabel P, Junker R, et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr. Dec 1999;158 Suppl 3:S113-6. [Medline].

240. Kollef MH, Zahid M, Eisenberg PR. Predictive value of a rapid semiquantitative D-dimer assay in critically ill patients with suspected venous thromboembolic disease. Crit Care Med. Feb 2000;28(2):414-20. [Medline].

241. Kontopoulou I. Oral contraceptives'' effects on the vascular component. Thrombophilic parameters. Ann N Y Acad Sci. 2000;900:228-36. [Medline].

242. Koren A, Zalman L, Levin C, et al. Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient. Pediatr Hematol Oncol. Sep-Oct 1999;16(5):469-72. [Medline].

243. Koster T, Rosendaal FR, Lieuw-A-Len DD, et al. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. Lancet. May 13 2000;355(9216):1694-5. [Medline].

244. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol. May 2000;182(5):1089-92. [Medline].

245. Kovacs MJ, Anderson D, Morrow B, et al. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. Feb 2000;83(2):209-11. [Medline].

246. Kraaijenhagen RA, in''t Anker PS, Koopman MM. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. Jan 2000;83(1):5-9. [Medline].

247. Kraimps JL, Dib H, Raynier P, et al. Left-sided inferior vena cava and thrombosis. Eur J Surg. Aug 1993;159(8):441-3. [Medline].

248. Kucherov AL. [Organization of antituberculosis care under the new economic conditions]. Probl Tuberk. 1991;(6):5-8. [Medline].

249. Kuismanen K, Savontaus ML, Kozlov A, et al. Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample. Forensic Sci Int. Dec 6 1999;106(2):71-5. [Medline].

250. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int Angiol. Jun 1999;18(2):83-102. [Medline].

251. LaCapra S, Arkel YS, Ku DH, et al. The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. Blood Coagul Fibrinolysis. Jun 2000;11(4):371-7. [Medline].

252. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. Mar 1 2000;95(5):1517-32. [Medline].

253. Langan EM 3rd, Miller RS, Casey WJ 3rd, et al. Prophylactic inferior vena cava filters in trauma patients at high risk: follow-up examination and risk/benefit assessment. J Vasc Surg. Sep 1999;30(3):484-88. [Medline].

254. Larsen TB, Norgaard-Pedersen B, Lundemose JB, et al. Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. Thromb Res. May 15 2000;98(4):233-9. [Medline].

255. Lassen MR, Borris LC, Jensen HP. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost. Jan 2000;6(1):53-7. [Medline].

256. Lau LL, McMurray AH. Mesenteric venous thrombosis in protein S deficiency: case report and literature review. Ulster Med J. May 1999;68(1):33-5. [Medline].

257. Le Blanche AF, Siguret V, Settegrana C, et al. Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years old. Angiology. Nov 1999;50(11):873-82. [Medline].

258. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. Sep 21 1999;131(6):417-23. [Medline].

259. Lee WA, Hill BB, Harris EJ Jr, et al. Surgical intervention is not required for all patients with subclavian vein thrombosis. J Vasc Surg. Jul 2000;32(1):57-67. [Medline].

260. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). Sep 1999;78(5):285-91. [Medline].

261. Lewis MA, MacRae KD, Kuhl-Habich D, et al. Venous thromboembolism and oral contraceptives. Lancet. Oct 23 1999;354(9188):1470. [Medline].

262. Lindahl TL, Lundahl TH, Fransson SG, et al. Evaluation of an automated micro-latex D-dimer assay (Tina-quant on Hitachi 911 analyser) in symptomatic outpatients with suspected DVT. Thromb Haemost. Dec 1999;82(6):1772-3. [Medline].

263. Lindmarker P. Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient setting?. Haemostasis. Dec 1999;29 Suppl S1:84-8. [Medline].

264. Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group. J Intern Med. May 2000;247(5):601-6. [Medline].

265. Lippi G, Brocco G, Manzato F, et al. Relationship between venous thromboembolism and lipid or lipoprotein disorders. Thromb Res. Sep 15 1999;95(6):353-4. [Medline].

266. Lloyd G. Protocols for deep vein thrombosis. J Accid Emerg Med. Jul 1999;16(4):313-4. [Medline].

267. London NJ, Nash R. ABC of arterial and venous disease. Varicose veins. BMJ. May 20 2000;320(7246):1391-4. [Medline].

268. Lopez FF, Sweeney JD, Blair AJ, et al. Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant. Am J Hematol. Sep 1999;62(1):58-60. [Medline].

269. Loret de Mola JR, Kiwi R, Austin C, et al. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril. Jun 2000;73(6):1253-6. [Medline].

270. Lowe G, Woodward M, Vessey M, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost. Apr 2000;83(4):530-5. [Medline].

271. Lozano EA, Saba ZS, Culbertson C. Transcatheter management of innominate vein thrombosis prior to bidirectional cavopulmonary anastomosis. Catheter Cardiovasc Interv. Jan 2000;49(1):61-3. [Medline].

272. Luddington R, Jackson A, Pannerselvam S, et al. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost. Feb 2000;83(2):204-8. [Medline].

273. Ludwig M, Felberbaum RE, Diedrich K. Deep vein thrombosis during administration of HMG for ovarian stimulation. Arch Gynecol Obstet. Feb 2000;263(3):139-41. [Medline].

274. Lynch TG, Dalsing MC, Ouriel K, et al. Developments in diagnosis and classification of venous disorders: non- invasive diagnosis. Cardiovasc Surg. Mar 1999;7(2):160-78. [Medline].

275. Mackenzie AR, Laing RB, Douglas JG, et al. High prevalence of iliofemoral venous thrombosis with severe groin infection among injecting drug users in North East Scotland: successful use of low molecular weight heparin with antibiotics. Postgrad Med J. Sep 2000;76(899):561-5. [Medline].

276. MacLean RM, Feeney GP, Bowley SJ, et al. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. Br J Haematol. Oct 1999;107(1):210-2. [Medline].

277. Madden S, Porter TF. Deep venous thrombosis: prophylaxis in gynecology. Clin Obstet Gynecol. Dec 1999;42(4):895-901. [Medline].

278. Magee LA, Redman CW. A case report of acute pelvic thrombophlebitis missed by magnetic resonance imaging of the pelvic veins. Eur J Obstet Gynecol Reprod Biol. Feb 2000;88(2):203-5. [Medline].

279. Mahe I, Bergmann JF, Mahe E, et al. PEP trial. Pulmonary Embolism Prevention. Lancet. Jul 15 2000;356(9225):248; discussion 250-1. [Medline].

280. Makris M, Leach M, Beauchamp NJ, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood. Mar 15 2000;95(6):1935-41. [Medline].

281. Manco-Johnson MJ, Nuss R, Hays T, et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr. Apr 2000;136(4):446-53. [Medline].

282. Mant MJ, Russell DB, Johnston DW, et al. Intraoperative heparin in addition to postoperative low-molecular- weight heparin for thromboprophylaxis in total knee replacement. J Bone Joint Surg Br. Jan 2000;82(1):48-9. [Medline].

283. Margaglione M, D''Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. Dec 1999;82(6):1583-7. [Medline].

284. Marie I, Levesque H, Cailleux N, et al. [An uncommon cause of venous thrombosis]. Rev Med Interne. Jun 2000;21(6):557-8. [Medline].

285. Marinella MA, Kathula SK, Markert RJ. Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital. Heart Lung. Mar-Apr 2000;29(2):113-7. [Medline].

286. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. Aug 1 2000;89(3):640-6. [Medline].

287. Martinelli I, Cattaneo M, Taioli E, et al. Genetic risk factors for superficial vein thrombosis. Thromb Haemost. Oct 1999;82(4):1215-7. [Medline].

288. Marz W, Nauck M, Wieland H. The molecular mechanisms of inherited thrombophilia. Z Kardiol. Jul 2000;89(7):575-86. [Medline].

289. McColl MD, Ellison J, Greer IA, et al. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol. Feb 2000;108(2):272-4. [Medline].

290. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. Mar 9 2000;342(10):696-701. [Medline].

291. Meissner MH. Deep venous thrombosis in the trauma patient. Semin Vasc Surg. Dec 1998;11(4):274-82. [Medline].

292. Meissner MH, Caps MT, Bergelin RO, et al. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. J Vasc Surg. Nov 1995;22(5):558-67. [Medline].

293. Mercuri F, Giacomello R, Puglisi F, et al. Factor V leiden increases plasma F1+2 levels both in normal and deep venous thrombosis subjects. Haematologica. Apr 2000;85(4):386-9. [Medline].

294. Merli GJ. Deep vein thrombosis and pulmonary embolism prophylaxis in joint replacement surgery. Rheum Dis Clin North Am. Aug 1999;25(3):639-56, ix. [Medline].

295. Merli GJ. Low molecular weight heparin in the treatment of acute deep vein thrombosis and pulmonary embolism: A paradigm change in care. J Thromb Thrombolysis. Jun 2000;9 Suppl 1:S21-7. [Medline].

296. Merli GJ. Low-molecular-weight heparins versus unfractionated heparin in the treatment of deep vein thrombosis and pulmonary embolism. Am J Phys Med Rehabil. Sep-Oct 2000;79(5 Suppl):S9-16. [Medline].

297. Merli GJ. Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population. Clin Geriatr Med. Feb 2001;17(1):93-106. [Medline].

298. Miller JL. Study documents cost reduction with outpatient enoxaparin therapy. Am J Health Syst Pharm. Dec 15 1999;56(24):2508. [Medline].

299. Miranda AR, Hassouna HI. Mechanisms of thrombosis in spinal cord injury. Hematol Oncol Clin North Am. Apr 2000;14(2):401-16. [Medline].

300. Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: comparison between a score and empirical assessment. J Intern Med. Feb 2000;247(2):249-54. [Medline].

301. Misgav M, Berliner S. [Upper extremity deep vein thrombosis]. Harefuah. Feb 1 1999;136(3):224-9. [Medline].

302. Misgav M, Eldor A, Berliner S. [A new mutation in the prothrombin gene (G20210A) and the risk for venous and arterial thromboembolism]. Harefuah. Jul 2000;139(1-2):51-6. [Medline].

303. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. Jan 2000;83(1):14-9. [Medline].

304. Mitsis M, Ioannou H, Eleftheriou A, et al. Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele), in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome--a case report. Angiology. Apr 2000;51(4):325-9. [Medline].

305. Moldanado SA. Secondary analysis: expanding survey research by faculty members. Nurse Educ. Jul-Aug 1991;16(4):4-5, 15. [Medline].

306. Morange PE, Henry M, Tregouet D, et al. The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol. May 2000;20(5):1387-91. [Medline].

307. Morey SS. American Thoracic Society develops guidelines on diagnosis of venous thromboembolism. Am Fam Physician. Feb 15 2000;61(4):1194, 1196, 1198-99. [Medline].

308. Mori PG, Acquila M, Bicocchi MP, et al. More on the relationship between cystic fibrosis and venous thrombosis. Eur J Haematol. Jul 2000;65(1):82-3. [Medline].

309. Morimoto Y, Sugimoto T, Okada M, et al. Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy. Angiology. Jan 2000;51(1):61-8. [Medline].

310. Muir KW, Watt A, Baxter G, et al. Randomized trial of graded compression stockings for prevention of deep- vein thrombosis after acute stroke. QJM. Jun 2000;93(6):359-64. [Medline].

311. Munchow N, Kosch A, Schobess R. et al. Role of genetic prothrombotic risk factors in childhood caval vein thrombosis. Eur J Pediatr. Dec 1999;158 Suppl 3:S109-12. [Medline].

312. Murphy TP. Sharp recanalization of central venous occlusions. J Vasc Interv Radiol. Sep 1999;10(8):1131. [Medline].

313. Musil D. [Regression of deep venous thrombosis]. Vnitr Lek. Jan 2000;46(1):16-8. [Medline].

314. Muto P, Lastoria S. Use of radiolabeled peptides to image deep venous thrombosis and pulmonary embolism. J Nucl Med. Jun 2000;41(6):1065-6. [Medline].

315. Newton LJ, Krishnan A, Parapia LA. Born to clot: the European burden. Br J Haematol. Oct 1999;107(1):213. [Medline].

316. Nguyen A. Review and management of patients with the prothrombin G20210A polymorphism. Clin Appl Thromb Hemost. Apr 2000;6(2):94-9. [Medline].

317. Nishikawa H, Ideishi M, Nishimura T, et al. Deep venous thrombosis and pulmonary thromboembolism associated with a huge uterine myoma--a case report. Angiology. Feb 2000;51(2):161-6. [Medline].

318. Noel AA, Gloviczki P, Charboneau JW. Free-floating femoral vein thrombus in a patient with aspergillosis. Int Angiol. Mar 2000;19(1):75-8. [Medline].

319. Nowak-Gottl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation. Aug 17 1999;100(7):743-8. [Medline].

320. O''Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med. Oct 25 1999;159(19):2298-304. [Medline].

321. O''Donnell J, Mumford AD, Manning RA, et al. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. Jan 2000;83(1):10-3. [Medline].

322. O''Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol. Jul-Aug 2000;11(7):823-36. [Medline].

323. Odeh M, Pick N, Oliven A. Deep venous thrombosis associated with acute brucellosis--a case report. Angiology. Mar 2000;51(3):253-6. [Medline].

324. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d''Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. May 2000;83(5):657-60. [Medline].

325. Oral Contraceptive and Hemostasis Study Group. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Contraception. Jun 1999;59(6):345-55. [Medline].

326. Ordonez AJ, Carreira JM, Alvarez CR, et al. Comparison of the risk of pulmonary embolism and deep vein thrombosis in the presence of factor V Leiden or prothrombin G20210A. Thromb Haemost. Feb 2000;83(2):352-4. [Medline].

327. Orlando L, Colleoni M, Nole F, et al. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?. Ann Oncol. Jan 2000;11(1):117-8. [Medline].

328. Ostermann H. [Therapy of deep vein thrombophlebitis]. Internist (Berl). Jun 2000;41(6):597-8. [Medline].

329. Ouriel K, Gray B, Clair DG, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol. Mar 2000;11(3):295-8. [Medline].

330. Ouriel K, Green RM, Greenberg RK. The anatomy of deep venous thrombosis of the lower extremity. J Vasc Surg. May 2000;31(5):895-900. [Medline].

331. Owings JT, Gosselin RC, Battistella FD, et al. Whole blood D-dimer assay: an effective noninvasive method to rule out pulmonary embolism. J Trauma. May 2000;48(5):795-9; discussion 799-800. [Medline].

332. Palestro CJ. Diagnosing deep venous thrombosis: dawn of a new era?. J Nucl Med. Jul 2000;41(7):1224-6. [Medline].

333. Parker M. PEP trial. Pulmonary Embolism Prevention. Lancet. Jul 15 2000;356(9225):249; discussion 250-1. [Medline].

334. Patel NH, McLennan G, Shah H. Introduction of a PTFE-covered long, spiral-articulated Palmaz stent through a 10-F sheath using umbilical wrapping technique. J Vasc Interv Radiol. Sep 1999;10(8):1063-6. [Medline].

335. Patel NH, Plorde JJ, Meissner M. Catheter-directed thrombolysis in the treatment of phlegmasia cerulea dolens. Ann Vasc Surg. Sep 1998;12(5):471-5. [Medline].

336. Pavcnik D, Uchida B, Timmermans H, Keller FS, Rösch J. Square stent: a new self-expandable endoluminal device and its applications. Cardiovasc Intervent Radiol. Jul-Aug 2001;24(4):207-17. [Medline].

337. Pavcnik D, Uchida BT, Timmermans HA, Corless CL, O'Hara M, Toyota N. Percutaneous bioprosthetic venous valve: a long-term study in sheep. J Vasc Surg. Mar 2002;35(3):598-602. [Medline].

338. Pazzagli M, Mazzantini D, Cella G, et al. Value of thrombin-antithrombin III complexes in major orthopedic surgery: relation to the onset of venous thromboembolism. Clin Appl Thromb Hemost. Oct 1999;5(4):228-31. [Medline].

339. Pearson SD, Blair R, Halpert A, et al. An outpatient program to treat deep venous thrombosis with low- molecular-weight heparin. Eff Clin Pract. Sep-Oct 1999;2(5):210-7. [Medline].

340. Pecheniuk NM, Marsh NA, Walsh TP. Multiple analysis of three common genetic alterations associated with thrombophilia. Blood Coagul Fibrinolysis. Mar 2000;11(2):183-9. [Medline].

341. Pena-penabad C, Martinez W, del Pozo J, et al. Guess what! Superficial migratory thrombophlebitis. Thromboangiitis obliterans (Buerger''s disease). Eur J Dermatol. Jul-Aug 2000;10(5):405-6. [Medline].

342. PEP. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: (PEP) trial. Lancet. Apr 15 2000;355(9212):1295-302. [Medline].

343. Pereira de Godoy JM, Batigalia F. Bilateral pulmonary artery aneurysm associated with bilateral pulmonary thromboembolism, superior vena caval thrombosis, and Chagas'' disease--a case report. Angiology. Jul 2000;51(7):609-14. [Medline].

344. Perry C, Berliner S. [Progesterone and the risk of arterial and venous thrombosis]. Harefuah. Apr 15 1998;134(8):633-7. [Medline].

345. Phillips GW. Review of venous vascular ultrasound. World J Surg. Feb 2000;24(2):241-8. [Medline].

346. Phipp LH, Scott DJ, Kessel D, et al. Subclavian stents and stent-grafts: cause for concern?. J Endovasc Surg. Aug 1999;6(3):223-6. [Medline].

347. Piemontino U, Guiotto G, Rugiada F, et al. Abnormally high frequency of inherited pro-thrombotic conditions in subjects with recurrence of venous thrombosis. Thromb Haemost. Oct 1999;82(4):1359-60. [Medline].

348. Pineo GF, Hull RD. Prophylaxis of venous thromboembolism following orthopedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis. Thromb Haemost. Aug 1999;82(2):918-24. [Medline].

349. Pini M. Future prospects of prophylaxis for deep vein thrombosis. Blood Coagul Fibrinolysis. Aug 1999;10 Suppl 2:S19-27. [Medline].

350. Piovella F, Barone M. Long-term management of deep vein thrombosis. Blood Coagul Fibrinolysis. Aug 1999;10 Suppl 2:S117-22. [Medline].

351. Pittman C, Reddy M, Reddy ER. Radiological evaluation of inferior vena cava obstruction: pictorial essay. Can Assoc Radiol J. Dec 1999;50(6):376-83. [Medline].

352. Pless S, Pless TK, Dominguez H. Abnormalities and thrombosis of the inferior vena cava--a diagnostic dilemma. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. Sep 1993;159(3):312-3. [Medline].

353. Poulter NR. Risk of fatal pulmonary embolism with oral contraceptives. Lancet. Jun 17 2000;355(9221):2088. [Medline].

354. Prakash RK, Netrawali MS, Pradhan DS. Ineffectiveness of rifampicin in inhibiting RNA synthesis in Escherichia coli and T(4)-infected Escherichia coli cells after exposure to ultraviolet radiation. Biochim Biophys Acta. Apr 2 1975;383(4):435-40. [Medline].

355. Rauwerda JA, Rijbroek A, Vahl AC. [Deep venous thrombosis of the arm: etiology, diagnosis and therapy]. Ned Tijdschr Geneeskd. May 20 2000;144(21):1020-1. [Medline].

356. Ray CE Jr, Shenoy SS, McCarthy PL, et al. Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vasc Interv Radiol. Nov-Dec 1999;10(10):1330-4. [Medline].

357. Reekers JA, Blank LE. Iliocaval thrombosis: percutaneous treatment with hydrodynamic thrombectomy. Eur Radiol. 2000;10(2):326-8. [Medline].

358. Reilly BM, Evans A. Cost-effectiveness of low-molecular-weight heparins for deep venous thrombosis. Ann Intern Med. Mar 21 2000;132(6):508-9. [Medline].

359. Renner W, Koppel H, Hoffmann C, et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res. Jul 1 2000;99(1):35-9. [Medline].

360. Rhee RY, Gloviczki P, Luthra HS, et al. Iliocaval complications of retroperitoneal fibrosis. Am J Surg. Aug 1994;168(2):179-83. [Medline].

361. Rhodes JM, Cho JS, Gloviczki P, et al. Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity. J Vasc Surg. Jun 2000;31(6):1193-205. [Medline].

362. Ridker PM. Inherited risk factors for venous thromboembolism: implications for clinical practice. Clin Cornerstone. 2000;2(4):1-14. [Medline].

363. Robinson DL, Teitelbaum GP. Phlegmasia cerulea dolens: treatment by pulse-spray and infusion thrombolysis. AJR Am J Roentgenol. Jun 1993;160(6):1288-90. [Medline].

364. Rolfe MW, Solomon DA. Lower extremity venography : still the gold standard. Chest. Oct 1999;116(4):853-4. [Medline].

365. Rosen SF, Clagett GP. Prevention of venous thromboembolism. Curr Opin Hematol. Sep 1999;6(5):285-90. [Medline].

366. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost. Jan 2000;83(1):1-2. [Medline].

367. Rosendaal FR. Venous thrombosis: prevalence and interaction of risk factors. Haemostasis. Dec 1999;29 Suppl S1:1-9. [Medline].

368. Roussi J, Bentolila S, Boudaoud L, et al. Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients. Spinal Cord. Aug 1999;37(8):548-52. [Medline].

369. Roy S, Laerum F, Brosstad F, et al. Sequestrated thrombolysis: comparative evaluation in vivo. Cardiovasc Intervent Radiol. Mar-Apr 2000;23(2):131-7. [Medline].

370. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Oral contraceptives and venous thromboembolism. New Zealand Committee, RANZCOG. N Z Med J. May 26 2000;113(1110):196. [Medline].

371. Rubins JB, Rice K. Diagnosis of venous thromboembolism. Step-by-step approach to a still lethal disease. Postgrad Med. Jul 2000;108(1):175-80; quiz 16. [Medline].

372. Rubinstein R, Kolia F, Novitzky N. Prevalence of Factor V Leiden in three ethnic groups of patients with deep vein thrombosis in the Western Cape province of South Africa. Eur J Haematol. Jul 2000;65(1):78-9. [Medline].

373. Ruehm SG, Wiesner W, Debatin JF. Pelvic and lower extremity veins: contrast-enhanced three-dimensional MR venography with a dedicated vascular coil-initial experience. Radiology. May 2000;215(2):421-7. [Medline].

374. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: An adjunct to venous outcome assessment. J Vasc Surg. Jun 2000;31(6):1307-12. [Medline].

375. Salartash K, Lepore M, Gonze MD. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg. Jun 2000;231(6):789-94. [Medline].

376. Sandrick K. Using new D-dimer tests to rule out venous thromboembolism. CAP Today. Feb 2000;14(2):40-2, 44, 46-7. [Medline].

377. Savage SA, Young G, Reaman GH. Catheter-directed thrombolysis in a child with acute lymphoblastic leukemia and extensive deep vein thrombosis. Med Pediatr Oncol. Mar 2000;34(3):215-7. [Medline].

378. Schambeck CM, Hinney K, Gleixner J, et al. Venous thromboembolism and associated high plasma factor VIII levels: linked to cytomegalovirus infection?. Thromb Haemost. Mar 2000;83(3):510-1. [Medline].

379. Schneider DJ, Steyn PS, Mansvelt EP. Factor V Leiden mutation and the risk of thrombo-embolic disease in pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol. Aug 2000;91(2):197-8. [Medline].

380. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter- Directed Thrombolytic Therapy. J Vasc Interv Radiol. Mar 2000;11(3):279-87. [Medline].

381. Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res. Sep 1 2000;99(5):447-52. [Medline].

382. Sheppard DR. Activated protein C resistance: the most common risk factor for venous thromboembolism. J Am Board Fam Pract. Mar-Apr 2000;13(2):111-5. [Medline].

383. Siemens HJ, Gutsche S, Bruckner S, et al. Antiphospholipid antibodies in children without and in adults with and without thrombophilia. Thromb Res. May 15 2000;98(4):241-7. [Medline].

384. Sivera P, Bosio S, Bertero MT, et al. G20210A homozygosity in antiphospholipid syndrome secondary to systemic lupus erythematosus. Haematologica. Jan 2000;85(1):109-10. [Medline].

385. Spritzer CE, Arata MA, Freed KS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging. Radiology. May 2001;219(2):521-5. [Medline].

Keywords

deep vein thrombosis, venous thrombosis, thrombophlebitis, May-Thurner syndrome, Cockett syndrome, iliofemoral thrombosis, DVT, lower extremity thrombosis, lower-extremity thrombosis, leg thrombosis, lower extremity deep venous thrombosis, occlusions of the deep veins, below-knee thrombosis, venous thromboembolism, VTE, pulmonary embolus, pulmonary embolism, PE, post-thrombotic syndrome, postthrombotic syndrome, PTE

Contributor Information and Disclosures

Author

Eric K Hoffer, MD, Director, Vascular and Interventional Radiology, Associate Professor of Radiology, Section of Angiography and Interventional Radiology, Dartmouth-Hitchcock Medical Center
Eric K Hoffer, MD is a member of the following medical societies: American Heart Association, Radiological Society of North America, Society for Cardiac Angiography and Interventions, and Society of Interventional Radiology
Disclosure: Nothing to disclose.

Coauthor(s)

John J Borsa, MD, Consulting Staff, Department of Radiology, St Joseph Medical Center
John J Borsa, MD is a member of the following medical societies: American College of Radiology, American Society of Neuroradiology, Cardiovascular and Interventional Radiological Society of Europe, Radiological Society of North America, Royal College of Physicians and Surgeons of Canada, and Society of Interventional Radiology
Disclosure: Nothing to disclose.

Medical Editor

Anthony Watkinson, MD, Professor of Interventional Radiology, The Peninsula Medical School; Consultant and Senior Lecturer, Department of Radiology, The Royal Devon and Exeter Hospital, UK
Anthony Watkinson, MD is a member of the following medical societies: Radiological Society of North America, Royal College of Radiologists, and Royal College of Surgeons of England
Disclosure: Nothing to disclose.

Pharmacy Editor

Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.

Managing Editor

Douglas M Coldwell, MD, PhD,, Interventional Radiologist, Jane Phillips Medical Center, Bartlesville, Oklahoma
Douglas M Coldwell, MD, PhD, is a member of the following medical societies: American Association for Cancer Research, American College of Radiology, American Heart Association, American Physical Society, American Roentgen Ray Society, Society of Cardiovascular and Interventional Radiology, Southwest Oncology Group, and Special Operations Medical Association
Disclosure: Sirtex, Inc. Consulting fee Speaking and teaching

CME Editor

Robert M Krasny, MD, Resolution Imaging Medical Corporation
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.

Chief Editor

Kyung J Cho, MD, FACR, William Martel Professor of Radiology, Interventional Radiology Fellowship Director, University of Michigan Health System
Kyung J Cho, MD, FACR is a member of the following medical societies: American College of Radiology, American Heart Association, American Medical Association, American Roentgen Ray Society, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.

Related eMedicine topics:

Deep Venous Thrombosis and Thrombophlebitis

Superficial Thrombophlebitis

Thrombophlebitis, Superficial

Phlegmasia Alba and Cerulea Dolens
 
Deep Venous Thrombosis of the Upper Extremity

Pulmonary Embolism

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)